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CHAPTER I 
 
INTRODUCTION 
 
Overview 
Modern therapies to treat human disease are the product of thousands 
of years of empirical research with origins in the earliest of recorded human 
history.  These early texts often recorded symptoms and prescribed 
treatments based upon clinical observations. These early prescriptions were 
entirely composed of naturally occurring products such as plants (herbalism), 
animals, and minerals. The practice of compounding these different elements 
into a single suspension or tablet established the basis of modern 
pharmacology. With the increasing ability for scientists to uncover the 
molecular basis of human diseases, so too has increased our desire to develop 
treatments to address these findings. Coinciding with the birth of molecular 
medicine in the mid-twentieth century, we witnessed the emergence of 
intelligent or rational drug design.1 Most of the drugs developed during this 
early period sought to treat cancer.  While radiation was an effective therapy 
to treat local tumors, additional pharmacologics were needed to reach every 
organ of the body to treat metastatic disease.2 Many of these drugs have since 
been replaced by more targeted therapies in the treatment of cancer. 
However, a few of these early drugs have since been applied to the treatment 
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of other human conditions, particularly the rheumatic diseases.2 Developed 
more than half a century ago, methotrexate is the standard of care for the 
treatment of rheumatoid arthritis (RA), but its use in the management of this 
disease was unintended and discovered largely by serendipity.1,3-5 Here we 
will explore the history of this anchor drug and its proposed mechanism of 
action in the treatment of neoplastic and non-neoplastic disease.  
 
Origins of Methotrexate 
Folates are critical components of cellular division, and DNA and RNA 
synthesis. The synthetic form of folate, folic acid, was first isolated in the 
early 1940s and was found to exacerbate acute forms of leukemia when added 
to a patient’s diet.1,3,4 Conversely, additional studies found that decreasing 
dietary amounts of folic acid decreased the leukemia cell counts in patients. 
From these early observations, work began to design analogues of folic acid, 
which could be used to treat cancer, particularly leukemia. Aminopterin was 
designed to reduce proliferation of cancerous cells via the inhibition of folate. 
Seminal work by Sidney Farber, a pathologist at Harvard Medical School and 
Boston Children’s hospital, demonstrated that aminopterin produced 
remission in children diagnosed with acute lymphoblastic leukemia (ALL).1,2,6 
Even though this only produced brief remissions, it was proof of concept that 
folate antagonism could suppress the proliferation of malignant cells. Thus, 
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the clinical efficacy of aminopterin in the treatment of ALL cemented 
aminopterin as one of the world’s first chemotherapeutics.1  
Work that followed nearly a decade later by Sidney Futterman, 
Michael Osborn, and Frank Heunnekens identified dihydrofolate reductase 
(DHFR) from chicken liver as the enzyme responsible for the reduction of folic 
acid to metabolically active forms.1,7 Thus, blockade of DHFR was implicated 
as a therapeutic target of chemotherapeutic doses of aminopterin. Isolation of 
this enzyme allowed for the creation of potent inhibitors of DHFR. 
Specifically, another folate analog, methotrexate, was identified in a study of 
leukemia-bearing mice and when compared to aminopterin increased 
survival in these mice.1 The chemical structures of these two compounds are 
highlighted in Figure 1-1. From these initial data in mice, two reports found 
that methotrexate at very high doses cured women diagnosed with 
choriocarcinoma, a malignant trophoblastic cancer of the placenta.2  This was 
the first solid tumor to be cured by a drug in humans and stimulated interest 
in investigating the effects of methotrexate in additional forms of cancer.1,8 Of 
particular interest was the reduced side effect profile observed in the 
methotrexate-treated cohort. Compared to radiation or alkylating agents that 
can lead to infertility or additional malignancies, methotrexate monotherapy 
did not produce these deleterious effects.1 Today, methotrexate is currently 
used in the treatment of large cell or high grade lymphomas, head and neck 
cancer, breast cancer, bladder cancer, and osteogenic sarcoma.1 It is often 
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used in combination with other therapies including 6-mercaptopurine (6MP).  
Studies have shown that the combination of methotrexate, 6MP, vincristine, 
and prednisone improve patient outcomes in the treatment of ALL.1 In 
particular, a treatment regiment first prescribing methotrexate and following 
with 6MP in sequence improves cure rates.1   
Given the immunosuppressive potential of aminopterin and 
methotrexate in the treatment of malignancy, Gubner et al reported in 1951 
that proliferative responses of formalin injection in rat paws was abrogated 
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Figure 1-1. Chemical structures of aminopterin and methotrexate. In contrast 
to aminopterin, methotrexate contains an added methyl group in place of a hydrogen 
atom at the 10 position of the paraaminobenzoic acid moiety shown in red.  
Adapted from: Berg et al. Biochemistry. 2012. p750a. and St. Clair et al. Rheumatoid 
Arthritis. 2004. p303-305.  
 5 
with aminopterin treatment.1,9 Further, in a small population of patients 
with active rheumatoid arthritis, Gubner and colleagues showed that the 
overwhelming majority of patients treated with aminopterin developed 
reduced indices of disease activity.  When the therapy was stopped, the 
patients experienced relapse. The toxicities reported included nausea and 
diarrhea, even at low doses (1-2mg/day).1 Due to these discomforts, 
methotrexate, which closely resembles aminopterin, was substituted.1  
Patients were able to tolerate methotrexate reasonably well at low doses. The 
role of aminopterin, and later methotrexate, was also investigated in other 
non-neoplastic diseases including psoriasis, a chronic skin condition 
producing thick patches of irritated skin that manifest as red or white scales 
and similar therapeutic benefits were observed.1  It is interesting to note that 
this early report describing the therapeutic potential of methotrexate or other 
folate analogs was largely ignored for a quarter century. It would not be until 
the late 1980s that methotrexate is approved for the treatment of rheumatoid 
arthritis.10  
 
Mechanism of Action of Methotrexate 
Given the therapeutic potential for methotrexate in the treatment of 
these forms of cancer and even autoimmune disease, significant resources 
have been expended to investigate its mechanism of action. Bertino et al 
provided significant insight demonstrating that methotrexate is actively 
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transported into cells through reduced folate transporter 1 (RFT-1).11  
Methotrexate, like naturally occurring folates, is polyglutamated once taken 
up by the cell. Folates exist in cells as polyglutamates through the addition of 
6 glutamyl groups in a gamma peptide linkage to the folate substrate using 
the enzyme folylpolyglutamate synthase (FPGS).12 These long-lived 
methotrexate polyglutamates remain in the liver of patients for a long period 
as well as in the bone marrow myeloid precursors.12  Polyglutamation of 
methotrexate occurs within 12-24 hours after treatment and polyglutamates 
constitute the active form of the drug.12,13 Thus, methotrexate is commonly 
referred to as a pro-drug, a compound that undergoes a biochemical 
modification to become its active form. Summarized in Figure 1-2, inhibition 
of DHFR, at pharmacologically relevant doses of MTX required for the 
treatment of malignancy, inhibits purine, pyrimidine, and thymidylate 
biosynthesis through reduced levels of tetrahydrofolate (FH4) in the cell. 
Blockade of these enzymes, which are critical for nucleotide generation, halts 
rapid division of tumor cells through induction of apoptosis. Thus, one goal of 
methotrexate therapy is to increase the cellular cytotoxicity profile.  
Alterations to this pathway in the form of mutated RFT-1 or DHFR can lead 
to methotrexate resistance in cancer patients.2,12 Interestingly, cancer 
subjects resistant to methotrexate often exhibit increased levels of DHFR 
protein.  
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It is hypothesized that gene amplification events may take place that are 
long-lived in tumor cells or that amplification occurs through 
extrachromosomal elements, called amplisomes, that contain DHFR genes.12 
This is currently an area of active exploration and future studies are required 
to determine the exact mechanisms.  
While methotrexate is still used in the modern treatment of cancer, it 
is in the treatment of rheumatoid arthritis that physicians have observed 
methotrexate’s greatest, long-term effectiveness. Often heralded as the drug 
Figure 1-2. Mechanism of action of methotrexate. Methotrexate (MTX) enters 
the cell through the reduced folate carrier (a) using an endocytic pathway activated 
by a folate receptor (b). After entering the cell, methotrexate is polyglutamated 
(Glu) by the enzyme folylpolyglutamate synthase (c). Methotrexate and its 
polyglutamates inhibit the enzyme dihydrofolate reductase (d), thereby blocking the 
conversion of dihydrofolate (FH2) to tetrahydrofolate (FH4). As tetrahydrofolate 
stores are depleted, thymidylate (TMP) synthesis (e) is reduced,which ultimately 
inhibits DNA synthesis (f). Long-chain polyglutamates of MTX have the same 
affinity as MTX for the target enzyme dihydrofolate reductase, but have markedly 
increased inhibitory effects on both thymidylate synthesis (e) and purine 
biosynthesis (f), which is required for RNA production. 
Reprinted with permission from: Chabner, B.A. et al. “Chemotherapy and the war on 
cancer.” Nature Reviews Cancer. 2005. 5:65-72. License No. 3346060430859 
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that revolutionized the field of rheumatology, low-dose, once-weekly 
methotrexate differs by approximately three orders of magnitude (milligrams 
versus grams) compared to dosing schemes required for the treatment of 
malignancies. When the FDA first approved methotrexate in 1988 for the 
treatment of rheumatoid arthritis, it was assumed that the mechanism of 
action by which methotrexate exerts its anti-inflammatory effects in 
rheumatoid arthritis would closely resemble the mechanism of action found 
in the treatment of cancer. Rheumatoid arthritis is a chronic, inflammatory 
condition of the small and large joints characterized by inflammation of the 
synovium, or lining of the joint (Figure 1-3).  While the precise etiology of this 
disease remains unknown, the growing appreciation for the molecular basis 
of this disease has provided several clues. At the heart of these analyses are 
the cell types found in the joint spaces of patients with active disease.  
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Lymphocytes are the most common cell infiltrate found in the synovial 
space.  In fact, of these lymphocytes, the majority are T lymphocytes making 
up approximately 30-50% of all cell types. Of the T lymphocytes found in the 
RA joint, it has been reported that the majority are CD4+ CD45RO+ memory 
cells.14  B cells constitute about 5% of the sublining synovial cells.14 Clonal 
expansion of the B cells in the joint spaces of RA subjects suggests a 
maturation process driven by an antigen, which still remains unidentified. In 
normal tissue, the synovial space is only 1 or 2 cells in depth and is 
Figure 1-3. Histopathologic appearance of rheumatoid arthritis (RA) 
synovial tissue. The synovium in RA is marked by intimal lining hyperplasia, 
infiltrating mononuclear cells in the sublining, and occasional lymphoid 
aggregates. 
Reprinted with permission from: Bartok, B. et al. “Fibroblast-like synoviocytes: 
key effector cells in rheumatoid arthritis.” Immunological Reviews. 2010. 
233:233-255. License No. 3346060644068. 
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comprised of both Type A (macrophage-like) and Type B (fibroblast-like) 
cells.14  However, in active rheumatoid arthritis this number increases ten-
fold and is primarily thought to be the consequence of hypercellularlity due to 
the increase of both Type A and Type B cells.14,15 Many studies have 
suggested that Type A cells in RA display an activated phenotype and due to 
circulation are constantly replenished from the bone marrow.  Locally, while 
in the joint spaces, these Type A, macrophage-like cells produce “pro-
inflammatory cytokines, chemokines, and growth factors” that in turn 
activate fibroblast-like synoviocytes and induce these cells to produce 
additional pro-inflammatory mediators including “IL-6, prostanoids, and 
matrix metalloproteinases.” 14 This process can create both paracrine and 
autocrine signaling networks that give rise to the chronic synovitis and 
recruitment of additional immune cells to the joint, which eventually erodes 
the extracellular matrix and destroys the joint space. This phenomenon is 
referred to as the ‘pannus’, an expansive synovial tissue.14 Phenotypically, 
this pannus closely resembles a tumor.  Nuclear factor κB (NF-κB), a 
transcription factor that is ubiquitously expressed and functions as a critical 
regulator of cell proliferation, differentiation, and inflammation, is also 
overexpressed in the RA synovium. Briefly, nuclear factor κB consists of five 
proteins, c-Rel, RelA (p65), RelB, p50/p105, and p52/p100 that form either a 
homodimer or heterodimer.14 c-Rel, RelA, and RelB function as the major 
transactivation subunits. Unless activated, these subunits reside in the 
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cytoplasm along with their inhibitor, IκB.14  Phosphorylation of IκB causes 
IκB to be degraded by the proteasome, thus releasing NF-κB dimers to 
migrate to the nucleus where they will target the promoter regions of target 
genes.14 Electromobility shift assays show constitutively high levels of p50 
and p65 expression in the synovium of rheumatoid arthritis subjects and 
induction of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α 
through IKK signaling pathways.16 Depletion of p65 or the IKK family 
member, IKKβ, in the synovial tissue with siRNAs or introduction of 
dominant negative mutants reduces levels of these pro-inflammatory 
cytokines.17 In addition to increased levels of NF-κB, both synoviocytes and T 
cells in RA exhibit defects in expression of the guardian protein p53 leading 
to inability for these cells to undergo apoptosis and loss of genomic 
integrity.15,18 p53 is a critical regulator of cell cycle progression and reduced 
p53 levels have also been found in a number of cancers including leukemia.  
Linking the contribution of these observations to the pervasive, non-resolving 
inflammation found in RA is a common goal in the management of the 
disease. Without this understanding, most therapeutics lack the specificity to 
precisely target the underlying defects contributing to disease progression. As 
such, most newly developed biologic agents attempt to disrupt the 
downstream, NF-κB activation-pro-inflammatory cytokine loop, by using 
drugs like Enbrel (etanercept), which selectively blocks the inflammatory 
cytokine, TNF-α.19 These newer biologic therapies have added to the ability of 
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physicians to improve outcomes and decrease disability.  However, despite 
these advances excess mortality observed in patients with RA continues and 
recent data suggest that the mortality gap between RA patients and the rest 
of the population continues to widen.20,21  
Given the pro-inflammatory, anti-apoptotic phenotype exhibited by 
both synoviocytes and T cells in RA, and the ability of methotrexate to 
mitigate indices of inflammation it is logical to question if methotrexate may 
exert its anti-inflammatory properties through modulation of these 
pathways.  For the past 30 years, the precise mechanism employed by 
methotrexate to exert its anti-inflammatory effects in RA has been the focus 
of thorough investigation.1,11,22-35 In the treatment of cancer, methotrexate 
induces apoptosis by blocking the folate-dependent processes involved with 
DNA and RNA synthesis ultimately leading to cell death. Curiously, however, 
folic or folinic acid supplementation in RA patients receiving methotrexate 
did not reverse its anti-inflammatory effects in randomized, blinded 
trials.1,3,34,36 Thus, other mechanisms have been proposed. A prevailing 
theory is that methotrexate exerts its mechanism of action through a number 
of different mechanisms including release of adenosine that function in 
parallel to blockade of nucleotide synthesis.3 Reduced levels of methyl donors 
including tetrahydrofolate (FH4) and methyltetrahydrofolate through 
inhibition of DHFR blocks generation of lymphotoxic polyamines through 
methionine and S-adenosylmethionine (SAM).4,5,13,30,34,36 Polyamine reduction 
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has been posited as one anti-inflammatory mechanism since polyamines can 
be converted to lymphotoxins.36 However, use of 3-deazaadensoine, a 
transmethylation inhibitor, did not demonstrate a significant clinical benefit 
in RA patients.36 Yet, low-doses of methotrexate also inhibit chemotaxis in 
monocytes through a process reversed by S-adenosylmethionine supporting 
the contribution of this pathway in RA.37 The retention of methotrexate 
polyglutamates in cells exceeds its half-life in plasma, suggesting that the 
methotrexate metabolites persist in tissues. These polyglutamates have also 
been shown to inhibit aminoimidazolecarboxamidoribonucleotide (AICAR) 
transformylase resulting in elevated intracellular AICAR levels.  RA subjects 
exhibit high levels of AICAR in their urine during the course of methotrexate 
therapy.3,36  Increased AICAR levels are strong inhibitors of adenosine 
monophosphate (AMP) and adenosine deaminase, involved in the 
consumption of AMP and adenosine to IMP and inosine. Accumulation of 
adenosine in tissues has anti-inflammatory effects and AICARriboside, which 
also inhibits adenosine deaminase, is increased in RA.36,38 Methotrexate has 
also been shown to enhance vasodilation leading to increased blood flow 
through inhibition of adenosine deamination in whole blood in humans.39  
The direct quantification of methotrexate-mediated adenosine release in 
humans receiving methotrexate has been unsuccessful largely because the 
half life of adenosine in blood and tissue is very brief making these 
measurements technically challenging.36,40 In animal models, however, the 
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anti-inflammatory effects of methotrexate have been shown to be mediated by 
adenosine using the carrageenanan-induced air pouch model of inflammation 
and reversals with A2A adenosine receptor antagonists and supplementation 
of adenosine deaminase.36,41 Figure 1-4 summarizes this pathway. 
 
Figure 1-4. Proposed mechanisms of the anti-inflammatory actions of 
methotrexate. Methotrexate exerts its anti-inflammatory actions through a number 
of cellular mechanisms. Competitive inhibition of dihydrofolate reductase diminishes 
the de novo synthesis of purines and pyrimidines by preventing the regeneration from 
dihydrofolate of tetrahydrofolate, which is essential for the generation of folate 
cofactors required for purine and pyrimidine synthesis. Reduction of the levels of 
methyl donors, such as tetrahydrofolate and methyltetrahydrofolate, by the inhibition 
of dihydrofolate reductase results in the inhibition of the generation of lymphotoxic 
polyamines through methionine and SAM. Inhibition of AICAR transformylase results 
in an increase in intracellular AICAR levels. This increase has potent inhibitory 
effects on AMP deaminase and adenosine deaminase, which are involved in the 
catabolism of AMP and adenosine to IMP and inosine, respectively. The consequent 
accumulation of adenosine confers anti-inflammatory effects. Levels of AICARriboside, 
a metabolite of AICAR, also accumulate and inhibit adenosine deaminase.  
Abbreviations: AICAR, aminoimidazolecarboxamidoribonucleotide; AICARriboside, 
aminoimidazolecarboxamidoribonucleoside; AMP, adenosine monophosphate; FPGS, 
folyl polyglutamate synthase; IMP, inosine monophosphate; SAH, S-
adenosylhomocysteine; SAM, S-adenosylmethionine. 
Reprinted with permission from: Chan, E.S. et al. “Methotrexate—how does it really 
work?” Nature Reviews Rheumatology. 2010. 6:175-178. License No. 346060792647 
 
 15 
Other studies have also shown that MTX inhibits T cell activation, 
induces apoptosis, and alters expression of T cell cytokines and adhesion 
molecules.22,26,42,43 Additional work by Phillips et al posit that the anti-
inflammatory properties of MTX are critically dependent upon the ability to 
produce reactive oxygen species in both T cells and monocytes, which 
ultimately lead to apoptosis.25 Given the pronounced anti-inflammatory 
properties of low-dose MTX therapy in RA, it is unclear how the known 
biochemical pathways affected by MTX, e.g. inhibition of DHFR, activation of 
adenosine synthesis and release, should produce this anti-inflammatory 
profile.  Our work has sought to explore the question of whether either 
additional biochemical pathways are targeted by methotrexate or additional 
biochemical consequences of DHFR inhibition by methotrexate may produce 
these anti-inflammatory properties observed in subjects with RA receiving 
low-dose MTX as therapy.  
 
The Cell Cycle and Cell Cycle Checkpoints 
The process by which eukaryotic cells reproduce is known as the cell 
cycle. This process leads to precise duplication of the organism’s genome and 
segregation of chromosomes into daughter cells.44 It is important to study 
how the cell cycle is regulated and organized since proliferation is one of the 
most fundamental activities of cells and completion of cell division is 
essential for the development of all organisms.45 It is also required for the 
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production of gametes and hence propagates survival of species.44 
Identification and understanding of the molecular mechanisms of cell cycle 
control provides potential targets that can be manipulated to control cell 
growth in a variety of complex diseases such as cancer.46,47  
Mitosis was the first cell cycle stage observed in salamander cells by 
Walther Flemming in 1878.48 Later, in the 1950s, DNA was shown to be the 
genetic material of all cells, the crystal structure was determined, and DNA 
was subsequently shown to be synthesized during a discrete period of 
interphase, termed the S phase, flanked by gap phases.44,45 Today, we 
appreciate that the cell cycle has four phases: the G1 phase, S phase, G2 
phase, and M phase.44 Cells can exit the cell cycle between the M and G1 
phase through cell death or apoptosis, or quiescence termed G0, and 
subsequently re-enter at G1.44 This process is summarized in Figure 1-5.  
Figure 1-5. The basic stages of the cell cycle. Adapted from: Alberts et al. 
Molecular Biology of the Cell. 2012   
G1 
phase 
S 
phase 
G2 
phase 
M 
phase 
G1 
phase 
!Interphase 
Cell death, 
apoptosis or 
senescence 
GO 
Quiescence 
 17 
These phases last for varying amounts of time, but in a typical mammalian 
cell, such as a cultured fibroblast, the total cell-cycle length is approximately 
24 hours in length. The G1 phase lasts between 12-15hrs, the S phase lasts 
between 6-8hrs, G2 lasts 5hrs, and mitosis (M) lasts for approximately 1hr.44 
Understanding the signals and mechanisms responsible for triggering cell-
cycle transitions remains an area of active investigation.46  
Major advancements in the field were accomplished through a series of 
experiments utilizing the power of yeast genetics and amphibian and marine 
invertebrate biological systems.45,49 Maturation promoting factor (MPF), also 
referred to as mitosis promoting factor, which drives the cell into mitosis, was 
identified in oocytes and subsequently biochemically purified by Lohka and 
Maller.50 Prior to MPF isolation, through a series of yeast studies by Leland 
Hartwell and Paul Nurse, temperature-sensitive cell division cycle (cdc) 
mutants were isolated in two strains of yeast and it was found that cdc2 was 
required for cell cycle progression.45 Cdc2 was later identified as a principal 
component of MPF.45,51-56 Concurrent with this observation, it was noticed 
that proteins accumulate cyclically in eggs and embryos of marine 
invertebrates and these proteins were named cyclins. In these experiments, 
cyclin concentration correlates with maximal MPF activity and one of these 
cyclins, Cyclin B, was isolated from sea urchin eggs by Tim Hunt and 
identified as another critical component of MPF.45,57,58 Collectively, these 
findings led to the 2001 Nobel Prize in Physiology or Medicine for discoveries 
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of these key regulators of the cell cycle and form the basis for today’s 
fundamental understanding of the cell cycle.49  
Cyclins are cyclin dependent kinase or CDK regulator subunits that 
are essential for kinase activity of the Cdk.44 They help to recruit substrates 
and target the complex to subcellular locations and govern duration of the 
CDK active state.44 Cdc2 was the first recognized CDK, and was 
subsequently renamed Cdk1 or cyclin-dependent kinase 1. Yeast have only 1 
Cdk, but contain multiple cyclins.44  Higher organisms have multiple cyclins 
and multiple Cdks.44 Major Cdks and cyclins of higher eukaryotes for the 
different cell-cycle phases are G1: Cdk4, Cdk6, and Cyclin D; G1/S: Cdk2 and 
Cyclin E; S: Cdk2 and Cyclin A; and M: Cdk1 and Cyclin B.44 Cyclin levels 
oscillate throughout the cell cycle regulating Cdk activity such that cyclical 
activation of Cdks drive cell-cycle transitions.46,59  
Since Cdk-cyclin complexes drive the cell cycle forward, a major 
question moving forward was what controls the activity of these complexes?45 
Methods for regulating CDK-cyclin activity include phosphorylation and 
dephosphorylation of Cdk, addition of subunits (inhibitors), control of 
intracellular localization, and degradation of cyclin and inhibitor 
subunits.44,60,61 One example of such regulation includes the phosphorylation 
event on Cdk1.46 It was found that Wee1 kinase inhibits mitotic entry 
resulting in a ‘stop’ event in the cell cycle whereas Cdc25 phosphatase 
promotes mitotic entry.62 Cdk inhibitors (CKIs) are also key negative 
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regulators of G1/S phase transition.63-65 There are two classes of CKIs: INKs 
which are inhibitors of kinases and cyclin/kinase inhibitory proteins 
(CIPs/KIPs).49 INKs when bound to the Cdk/Cyclin molecule trigger release of 
cyclin thus inactivating the cell cycle at the G1/S phase.  CIPs/KIPs inhibit 
kinase activity by binding to the Cdk-cyclin complex. Two examples of this 
particular class of inhibitor are p21 (CIP) and p27 (KIP1).  In humans, these 
two proteins are transcribed by the genes CDKN1A and CDKN1B, 
respectively.46,63,65 Nuclear accumulation of Cdk1-cyclin B1 complexes and 
Cdc25C in late prophase is required for mitosis. Phosphorylation of Cyclin B1 
and Cdc25 leads to their nuclear accumulation. Lastly, degradation of Cyclin 
B at various stages during the cell cycle in Xenopus laevis embryos led to the 
discovery that cyclins are proteolyzed by the ubiquitin (Ub)-proteasome 
system.57,59,66,67 Ubiquitination of Cyclin B leads to degradation of Cyclin B by 
the proteasome.64,65,67 Thus, the cell cycle is both a protease-driven and 
kinase-driven process. Deregulation of various Cdk inhibitors has been 
documented in a variety of tumors.46 Typically, oncogenic changes are 
associated with decreased levels of Cdk inhibitors in tumors. Thus, an area of 
intense focus is understanding the regulation of these Cdk inhibitors in the 
context of malignancy.46  
It is currently estimated that 10,000 trillion cell replication events will 
have occurred in the lifetime of a human being.68 There are also greater than 
3-3.5 billion base pairs of DNA in a cell.68 Abnormalities in the process of cell 
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division can occur as the product of a variety of stresses, both internal and 
external.68,69 In fact, a cell typically accumulates in excess of 10,000 DNA 
lesions per cell in a given day.68 Checkpoints exist to prevent damaged cells 
from further progress in the cell cycle.69,70 Checkpoints also ensure the 
completion of one cell cycle phase prior to the onset of another phase.44 They 
also respond to DNA or microtubule stress to halt cell cycle progression to 
provide time for repair.44 Early evidence for cell cycle checkpoints was found 
in patients suffering from Ataxia Telangiectasia (AT). In normal eukaryotic 
cells, DNA synthesis is slowed and stopped before mitosis in response to 
ionizing radiation.71-73 However, patients suffering from AT continue from the 
S-phase and into mitosis.74 Patients present with the disease as early as 4-5 
years of age and often have a predisposition to immune deficiencies, cancer, 
neuro-degeneration, and often succumb to the disease by 20 years of age.74,75 
Molecularly, these patients exhibit a loss of G1, S, and G2/M checkpoints. 
Through a series of positional cloning experiments, a gene, ATM (ataxia 
telangiectasia mutated) was identified as the gene that was mutated in 
subjects with AT.76 Thus in the context of DNA damage-inducing agents, 
such as ionizing radiation or even normal cellular biochemistry, subjects with 
AT are unable to repair these damaged cells because of reduced function of 
ATM. 77  
Other sentinel regulators of the DNA damage response have been 
identified in addition to ATM and include ataxia-telangiectasia and Rad3-
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related (ATR), and checkpoint kinases CHK1 and CHK2. These pathways are 
activated in response to DNA damage and result in increased levels of p21 or 
blockade of CDK activators, such as Cdc25 phosphatase. These proteins in 
the DNA damage response are thought to have anticancer properties through 
maintenance of genome integrity via DNA repair and cell cycle arrest when 
necessary.46 In certain forms of cancer, these pathways are activated as 
measured by constitutive expression of phosphorylated H2AX and the tumor 
suppressor, p53.78,79 Often these markers are at their highest expression in 
“pre-invasive stages of human tumors and correlate with the presence of 
senescence markers”.46 This is often followed by a period of reduced DNA 
damage response through reduction in ATM, CHK2, and p53 expression 
leading to reduced expression of p21.46,80,81 These defects contribute to 
progression in the cell cycle despite damaged DNA thus leading to genomic 
instability and tumorigenesis.69,81,82  
Previous work conducted in our laboratory and the laboratory of others 
demonstrates that similar defects exist in human autoimmune disease. 
Specifically, ATM, CHK2, p53 and p21 are under-expressed in lymphocytes 
obtained from subjects with rheumatoid arthritis.18,83 These lymphocytes also 
accumulate DNA damage.84  It has been suggested that these defects 
contribute to increased genomic instability and entry into a phase of early 
senescence.85  In synovial tissue, which is the major site of inflammation and 
tissue destruction in rheumatoid arthritis, loss of function mutation have 
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been described that may also contribute to the hyperproliferative state of the 
synovium in rheumatoid arthritis.14,86 If or how these deficiencies may 
contribute to the chronic inflammatory state of rheumatoid arthritis is not 
known.  
The following four chapters will examine contributions of methotrexate 
in treating defects in apoptosis and cell cycle checkpoints and further 
investigate molecular mechanisms responsible for anti-inflammatory 
properties of methotrexate in the treatment of RA. These studies extend to 
both lymphocytes and fibroblast-like synoviocytes, key effector cells in RA 
pathogenesis. The first chapter examines the ability of methotrexate to 
induce apoptosis and demonstrates that increased JNK activation alters 
apoptosis sensitivity in cells treated with methotrexate. Methotrexate blocks 
the reduction of dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4), which 
results in increased reactive oxygen species in lymphocytes leading to 
activated JNK. In the second chapter, we demonstrate that methotrexate 
treatment increases expression of cell cycle checkpoints, p53 and p21, 
through activation of JNK via a BH4 and ROS-dependent mechanism. The 
third chapter examines the cell type specificity of this BH4 pathway and finds 
that reduced activity of NF-κB in T cells is dependent upon MTX-mediated 
blockade of BH4 and activation of JNK and induction of p53.  This is in 
contrast to synoviocytes where the adenosine pathway appears to be 
responsible for MTX-mediated inhibition of NF-κB.  In the final chapter, we 
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further examine the link between p53 and NF-κB in T cells by analyzing the 
downstream target of p53 activation, lincRNA-p21. This molecule belongs to 
a relatively new class of non-coding RNAs.  We find that lincRNA-p21, which 
is underexpressed in RA, is induced by MTX both in vitro and in vivo and 
inhibits NF-κB activity in T cells.  This process is independent of both the 
adenosine pathway and the BH4 pathway. Rather, induction of lincRNA-p21 
is critically dependent upon phosphorylation and activation of DNA-PKcs by 
methotrexate (Gene symbol: PRKDC), a sentinel of the DNA damage 
response.  
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CHAPTER II 
 
INCREASED SENSITIVITY TO APOPTOSIS INDUCED BY 
METHOTREXATE IS MEDIATED BY JNK 
 
Abstract 
 
Objective. Low-dose methotrexate is an effective therapy for 
rheumatoid arthritis (RA), yet its mechanism of action is incompletely 
understood. The aim of this study was to explore the induction of apoptosis by 
MTX.  
 Methods. Flow cytometry was performed to assess changes in the 
levels of intracellular proteins, reactive oxygen species (ROS), and apoptosis. 
Quantitative polymerase chain reaction was performed to assess changes in 
the transcript levels of select target genes in response to MTX.  
 Results. MTX did not directly induce apoptosis but rather “primed” 
cells for markedly increased sensitivity to apoptosis via either mitochondrial 
or death receptor pathways, by a JNK-dependent mechanism. Increased 
sensitivity to apoptosis was mediated, at least in part, by MTX-dependent 
production of ROS, JNK activation, and JNK-dependent induction of genes 
whose protein products promote apoptosis. Supplementation with 
tetrahydrobiopterin blocked these MTX-induced effects. Patients with RA 
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who were receiving low-dose MTX therapy expressed elevated levels of the 
JNK target genes, JUN.  
 Conclusion. Our results support a model whereby MTX inhibits 
reduction of dihydrobiopterin to tetrahydrobiopterin, resulting in increased 
production of ROS, increased JNK activity, and increased sensitivity to 
apoptosis. The finding of increased JUN levels in patients with RA receiving 
low-dose MTX supports the notion that this pathway is activated by MTX in 
vivo and may contribute to the efficacy of MTX in inflammatory disease.  
 
Introduction 
 
 The folic acid antagonist, methotrexate [MTX], was initially developed 
during the 1940s to inhibit dihydrofolate reductase [DHFR] for treatment of 
malignancies.87-89  The clinical potential of MTX in treating rheumatoid 
arthritis [RA] was initially suggested by Gubner in 1951, after studying the 
effects of MTX in six patients diagnosed with RA and was confirmed by 
further studies conducted during the 1980s.9,11,28,90,91  These studies had 
durations of 12 to 18 weeks, and dosages varied from 7.5 to 25 milligrams per 
week.  MTX possessed anti-inflammatory effects in RA patients, as trial 
subjects demonstrated improved function, global assessments, joint scores 
and marked decreases in pain.  Use of weekly low doses of MTX is not limited 
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to RA therapy.  Over the years, this treatment option has expanded to 
include additional inflammatory and autoimmune diseases.33,35,92,93 
In contrast to treatment of malignancy, much lower and more 
infrequent doses of MTX are used to treat inflammatory disease and basic 
mechanisms may differ greatly from those targeting cancer.  Exact 
mechanisms underlying anti-inflammatory actions of MTX remain 
inconclusive in spite of its widespread application.36  MTX, like natural 
folates, is polyglutamated once taken up by cells.  MTX-polyglutamates are 
believed to represent the active form of the drug and levels of MTX-
polyglutamates correlate with clinical efficacy in patients with RA.31,94  MTX 
stimulated synthesis of adenosine and its release by cells and subsequent 
activation of adenosine receptors may be one mediating factor contributing to 
anti-inflammatory actions of MTX.13,23,36  MTX also inhibits T cell activation, 
induces T cell apoptosis, and alters expression of T cell cytokines and 
adhesion molecules.22,26,42,43  Such actions may be partly mediated by 
synthesis and release of adenosine.  MTX action may also be dependent, in 
part, upon its ability to stimulate production of reactive oxygen species 
[ROS].25  
 From these studies, underlying mechanisms behind induction of 
apoptosis by low concentrations of MTX are not immediately apparent.  In 
general, cells undergo apoptosis via their ability to activate intrinsic 
[mitochondrial] or extrinsic [death receptor] pathways.95-101  For example, the 
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stress-inducible p53 protein plays a central role in transducing DNA damage 
signals to cause cellular apoptosis.  Death receptors, such as Fas or the 
family of TNF receptors transmit signals through adapter molecules such as 
Fas-associated death domain, TNFR-associated death domain or death 
domain-associated protein.  These adaptor proteins activate death caspases 
causing apoptotic cell death. Both intrinsic and extrinsic apoptosis pathways 
are thought to involve JNK signaling.101  Here, we sought to investigate 
induction of apoptosis by low concentrations of MTX in a transformed human 
T cell line.  We find that low concentrations of MTX do not directly induce 
apoptosis.  Rather, MTX markedly increases sensitivity of cells to apoptosis 
mediated via either death receptor or mitochondrial pathways, in part, by 
increasing expression of genes whose protein products play key roles in 
induction of apoptosis.  This alteration in the transcriptional profile of cells 
treated with MTX is dependent upon induction and activation of JNK by 
ROS. Apoptosis sensitivity and ROS production are prevented by 
supplementation with tetrahydrobiopterin [BH4] suggesting that inhibition of 
reduction of dihydrobiopterin [BH2] by DHFR initiates this pathway.  Studies 
of subjects with RA who are on current MTX therapy support the notion that 
these pathways may be activated, in vivo, by MTX and contribute to 
therapeutic efficacy of MTX.   
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Materials and Methods 
 
Drugs and Reagents.  MTX, adenosine, caffeine, theophylline, NAC, 
H2O2, and BI-78D3 were from Sigma. pepJIP1 was from Enzo Life Sciences. 
Anti-Fas antibody was obtained from Medical and Biological Laboratories, 
LTD. Caspase 3 activity was determined by enzymatic assay from Promega 
(CaspACE Colorimetric Assay System).  384-well apoptosis TLDA plates were 
from Applied Biosystems.  Plasmids containing JNK1 [MAPK8] and JNK2 
[MAPK9] dominant negative mutants were obtained from Addgene. 
Cell Preparation and Culture.  The human Jurkat T cell leukemia 
line was from ATCC.  PBMC were purified by Ficoll-Hypaque gradient 
centrifugation.  Cells were cultured in RPMI media with 10% FCS, Penn-
Strep, and L-glutamine in a 37°C atmosphere of 5% CO2 in air.  Cells were 
plated at 0.8 × 106 cells per ml in 5 ml cultures.  Cell viability and numbers 
were determined microscopically after staining with trypan blue. 
 Cell Transfection. Cells were transfected using the Amaxa Cell Line 
Nucleofector Kit V (Amaxa, Koeln, Germany). Briefly, 1x106 Jurkat T cells 
were resuspended in 100uL Cell Line Nucleofector Solution V containing 2µg 
of plasmid DNA and 2µg pmaxGFP vector.  The cell suspension was 
transferred to the provided cuvette and nucleofected using program X-001 on 
the Amaxa Nucleofector apparatus (Amaxa).   Cells were incubated at room 
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temperature for 10 minutes then transferred to pre-warmed culture medium 
in 6-well plates.  
Quantitative RT-PCR.  Total RNA was purified from blood collected 
in PAXgene tubes according to manufacturer's instructions [Qiagen] or from 
cell cultures using Tri-Reagent and quantified using a NanoDrop-1000 
spectrophotometer.  Five mg total RNA was used for cDNA synthesis 
[SuperScript III First-Strand Synthesis Kit, Invitrogen] with Oligo dT as the 
primer. RT-PCR reactions were prepared in duplicate in reaction volumes of 
25 ml with 50 ng cDNA, TaqMan assay mix, and TaqMan gene expression 
assay.  GAPDH was used as a housekeeping gene and control.  RT-PCR was 
performed using the ABI-7300 Real Time PCR System [Applied Biosystems]. 
 Western Blotting.  Whole cell lysates were prepared in PBS 
containing 1% NP-40 (Igepal CA 630), 50mm Tris HCl, 150mm NaCl, 2mm 
EDTA, 0.1% SDS, plus a cocktail of protease inhibitors [Roche] and sodium 
orthovanadate.  Equal amounts of protein were resolved by SDS-
polyacrylamide gel electrophoresis and transferred to PVDF membranes. 
Membranes were blocked in 5% nonfat milk, 0.1% Tween-20 in PBS.  Rabbit 
polyclonal antibodies to JNK1 [ab10664] and phosphorylated JNK1 [cross-
reactive with P-JNK2; P-JNK 1/2, ab4821] were from Abcam.  The ECL Plus 
Chemiluminescent Kit [Applied Biosystems] was used to visualize protein 
bands.   
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 Flow cytometry.  For apoptosis determinations, cells were labeled 
with the PE Annexin-V Apoptosis Detection Kit I from BD-Pharmingen.  For 
intracellular protein determinations, cells were fixed [paraformaldehyde], 
permeabilized [triton X-100 and NP-40], and labeled with primary antibodies 
for 24 hr at 0-4o C as described in the text followed by incubation with 
fluorescent-labeled secondary antibodies for 1 hr at 0-4oC.  The following 
antibodies were employed: primary antibodies, rabbit anti-JNK [Santa Cruz, 
sc-571], polyclonal rabbit anti-p-JNK [pT183/pY185] [BD Pharmingen 
558268], rabbit monoclonal to PUMA [abcam 33906], c-JUN [abcam, ChIP 
Grade [ab31419], TRAILR1 [DR4] [abcam 18362], and c-Fos antibody [abcam 
7963]. FITC goat anti-rabbit Ig [BD Pharmingen, 554020] was used as the 
secondary. Cells were analyzed using the 3-laser BD LSRII flow cytometer. 
 Patient Populations.  The study group was composed of 36 control 
subjects who had no current chronic or acute infections and no family history 
of autoimmune diseases and 70 subjects meeting the American College of 
Rheumatology clinical criteria for RA.  No other exclusion or inclusion 
criteria were employed except for the ability to provide informed consent. The 
Committees for the Protection of Human Subjects of Vanderbilt University 
and UT Southwestern Medical Center approved these studies.  The 
approximate female-to-male ratio in all study groups was 3:1.  Age ranges 
[36-58 years] and racial distributions in all groups were similar.  Current 
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therapies were determined by questionnaire and confirmed by chart review.  
Patients on MTX therapy were receiving doses of 15-25 mg per week.   
 Statistics.  Statistical significance was determined by the unpaired T 
test with Welch's correction.  P < 0.05 was considered significant.  
 
Results 
 
 Apoptosis “priming” by MTX. Various studies have demonstrated 
the ability of MTX to induce apoptosis or alter cell viability. We cultured 
Jurkat T cells with MTX and monitored apoptosis by measuring the activity 
of caspase 3. Jurkat cells cultured with MTX, low concentrations of either 
H2O2 or anti-Fas for 24 hours, or combinations of MTX and H2O2 or MTX and 
anti-Fas exhibited minimal activation of caspase 3 relative to cells cultured 
with high concentrations of H2O2 (Figure 2-1A). We next cultured cells for 48 
hours with MTX and then exposed them to either anti-Fas antibody or H2O2 
for an additional 24 hours to activate death receptor or mitochondrial 
apoptosis pathways, respectively. Pretreatment of Jurkat cells with MTX at 
concentrations of 0.1µM resulted in a marked increase in activity of caspase 3 
following culture with either H2O2 or anti-Fas (Figure 2-1B). As a second 
measure of apoptosis, we used flow cytometry to investigate changes in 
annexin V labeling. We used JNK1-DN and JNK2-DN mutants to assess the 
relative contributions of JNK1 and JNK2 to increased apoptosis sensitivity.  
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Figure 2-1. Methotrexate (MTX) primes Jurkat cells for increased sensitivity 
to apoptosis. A and B, Jurkat cells were cultured for 48 hours with MTX, H2O2, or 
50ng/ml anti-Fas (A) or were cultured for 48 hours with the indicated concentrations 
of MTX, followed by culture with H2O2 or anti-Fas for 24 hours (B), and the levels of 
caspase 3 were determined. C, JNK1-dominant negative (DN), JNK2-DN, or empty-
vector plasmids with a green fluorescent protein (GFP) plasmid were introduced by 
transient transfection. Cells were cultured for 48 hours with or without MTX 10-7 M 
and treated with anti-Fas for an additional 6 hours. The percentage of annexin V-
positive cells was determined by flow cytometry after gating on GFP-positive and 
GFP-negative cells. D and E, Jurkat cells were cultured for 48 hours with MTX (10-7 
M) in the presence or absence of BI-78D3 or pepJIP1 (D) or in the presence or absence 
of N-acetyl-L-cysteine (NAC) (E), followed by culture with anti-Fas for 6 hours. The 
percentage of annexin V-positive cells was determined by flow cytometry. Bars show 
the mean ± SD. * = P < 0.05 versus untreated cells.  
 33 
Jurkat cells, either untreated or cultured with MTX for 48 hours, exhibited 
low percentages of annexin-V positive cells. Treatment with H2O2 or anti-Fas 
only slightly increased the percentages of annexin-V positive cells. However, 
treatment of MTX-cultured cells with H2O2 or anti-Fas resulted in a marked 
increase in the percentage of annexin-V positive cells (Figure 2-1C). This 
increase in apoptosis (annexin-V-positive cells) was slightly abrogated by the 
presence of either JNK1-DN or JNK2-DN mutants but was substantially 
abrogated by the presence of both JNK1-DN and JNK2-DN mutants.  
 We also tested the ability of the specific JNK inhibitors BI-78D3 and 
pepJIP1, which target JNK-JNK interacting protein 1 interaction sites, to 
prevent apoptosis.102,103 Both inhibitors blocked MTX-dependent increases in 
sensitivity to apoptosis (Figure 2-1D). NAC, a free radical scavenger and 
reducing agents, also blocked MTX-dependent apoptosis (Figure 2-1E). Based 
on these results, we concluded that MTX primes cells for markedly increased 
sensitivity to apoptosis via death receptor and mitochondrial pathways, 
which is dependent on JNK1 and JNK2 enzymes. Additionally, ROS may 
contribute to increased apoptosis sensitivity.  
We next sought to determine whether MTX treatment of Jurkat cells 
altered the expression levels of a panel of genes who protein products are 
known to have activating or inhibitor effects on apoptosis. Jurkat cells were 
cultured with MTX for 48 hours prior to RNA isolation, cDNA synthesis, and 
analysis by quantitative PCR. Although we did not observe reduced 
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expression of genes such as BCL2, whose protein products protect cells from 
apoptosis (Supplementary Fig. 2-1), we observed increased expression of 
several genes, BBC3 (PUMA, Bcl-2 binding component 3), BCL3 (B cell 
CLL/lymphoma 3), HRK (hara-kiri), LTB (lymphotoxin β), TNFRSF10A 
(cytotoxic TRAIL receptor, TRAILR-1), TNFSF10 (TRAIL, APO2L), 
TNFRSF1B (TNFR2), and TNFRSF25 (TRAMP, APO-3), whose protein 
products are known to play critical roles in promoting sensitivity to apoptosis 
(Figure 2-2A). We also investigated changes in expression of the prototypical 
JNK target genes, JUN and FOS. These genes also had increased expression 
levels following MTX treatment.  
To assess changes in the protein levels of target genes and to assess 
the relative contributions of JNK1 and JNK2 to these changes, we measured 
intracellular protein levels by flow cytometry with specific antibodies and 
used JNK1- or JNK2-DN mutants to specifically inhibit JNK1 or JNK2. MTX 
treatment resulted in increased protein expression of the known JNK target, 
c-Jun, and this increase was inhibited by the JNK1-DN mutant but not the 
JNK2-DN mutant (Figure 2-2B). We also determined changes in TRAILR-1, 
c-Fos, and PUMA protein levels after MTX treatment in the presence of 
either JNK1- or JNK2-DN mutants, using flow cytometry.  
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Figure 2.  MTX induces expression of genes whose protein products promote apoptosis.  [A] Jurkat 
cells were cultured with MTX for 48 hr.  RNA was isolated followed by cDNA synthesis.  Transcript 
levels of genes whose protein products are known to influence apoptosis were determined using the 
384-well TLDA apoptosis plate [Sup. Figure 1].  Results are expressed as fold increase in transcript 
levels over untreated Jurkat cells after normalization to GAPDH levels.  [B] JNK1-DN, JNK2-DN or 
'empty vector' plasmids with a GFP expression plasmid were introduced into Jurkat cells by 
nucleofection.  Cultures were treated with MTX, 10-7 M, for 48 hrs, harvested, fixed and 
permeabilized, labeled with antibodies specific for the indicated proteins and fluorescent labeled 
secondary antibody, and analyzed by flow cytometry.  Left panel: black line, c-Jun levels in untreated 
cells, blue line, c-Jun levels in MTX treated cells, red line, c-Jun levels in MTX treated cells 
transfected with JNK1-DN, middle panel: black line, c-Jun levels in untreated cells, blue line, c-Jun 
levels in MTX treated cells, red line, c-Jun levels in MTX treated cells transfected with JNK2-DN.  
Right panel: Mean changes in expression levels of c-Jun, Fos, PUMA and TRAILR1 in MTX treated 
Jurkat cells determined by flow cytometry expressed as fold change relative to untreated Jurkat cells ± 
S.D. [C] Inhibition of MTX-mediated increases in c-Jun and Fos protein levels by specific JNK 
inhibitors, BI-78D3 or pepJIP1 relative to untreated Jurkat cells ± S.D.  * P < 0.05 relative to protein 
levels in MTX-treated Jurkat cells.!
A B 
C 
Figure 2-2. MTX induces expression of genes whose protein products promote 
apoptosis. A, Jurkat cells were cultured with MTX for 48 hours, and transcript levels of 
genes whose protein products are known to influence apoptosis were determined. Results 
are expressed as the fold increase compared with untreated cells after normalization to 
GAPDH. B, JNK1-DN, JNK2-DN, or empty-vector plasmids with a GFP expression 
plasmid were introduced into Jurkat cells by nucleofection. Left and middle, C-Jun levels 
in untreated cells (black lines), MTX-treated cells (blue lines), and MTX-treated cells 
transfected with JNK1-DN (red lines; left) or MTX-treated cells transfected with JNK2-DN 
(red lines; middle) are shown. Right, Ch nges in the expression levels of c-Jun, Fos, 
PUMA, and TRAILR-1 in MTX-treated Jurkat cells were determined by flow cytometry 
and are expressed as the fold change relative to untreated cells. C, MTX-mediated 
increases in c-Jun a d Fos protein levels were inhibited by the specific JNK i hibitors BI-
78D3 and pepJIP1. Bars show the mean ± SD. * = P < 0.05 versus untreated cells. Max = 
maximum (see Figure 2-1 for other definitio s).  
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Induction of TRAILR-1 by MTX was also abrogated by the JNK1-DN mutant, 
whereas the induction of c-Fos and PUMA was relatively unaffected by the 
JNK1-DN mutant but was almost completely abrogated by the JNK2-DN 
mutant (Figure 2-2B). The JNK-specific inhibitors BI-78D3 and pepJIP1 also 
inhibited induction of c-Jun and c-Fos expression by MTX (Figure 2-2C).  
 Taken together, these results provided evidence that MTX increased 
sensitivity to apoptosis, at least in part, by inducing expression of genes 
whose protein products promote apoptosis. The results observed with the 
JNK-DN mutants implicated both JNK1 and JNK2 as regulators of this gene 
family.  
Induction of JUN and FOS by MTX. JUN and FOS are prototypical 
JNK target genes.104,105 Thus, we further explored induction of these genes by 
MTX. We also examined the effects of adenosine, because MTX is known to 
induce adenosine production.36 MTX at concentrations of 0.1-1.0µM 
stimulated a gradual increase in JUN levels over the course of 24-72 hours 
(Figure 2-3A). In contrast, adenosine at concentrations of 0.01-100µM failed 
to induce changes in JUN expression levels over this time period (Figure 2-
3B). This range of adenosine concentrations should be sufficient to activate 
known human adenosine receptors, which have 50% maximum response 
concentrations for adenosine of ~0.3µM to 30µM.106-108  
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Figure 2-3. Induction of JUN and FOS expression by methotrexate (MTX) in Jurkat T 
cells. A-D, Jurkat T cells were cultured with the indicated concentrations of MTX (A and C) or 
adenosine (B and D). At the indicated times, cell cultures were harvested, total RNA was purified, 
and cDNA was synthesized. The relative expression of JUN and FOS was normalized to GAPDH 
levels and expressed as the fold induction relative to untreated cultures. E and F, Jurkat cells 
were also cultured with MTX and the adenosine receptor antagonists caffeine (20 µM) and/or 
theophylline (20 µM) for 48 hours. The expression levels of JUN and FOS were determined by 
polymerase chain reaction. Bars show the mean ± SD. * = P < 0.05 versus unstimulated cultures.  
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We also determined the expression levels of JUN family members, JUNB and 
JUND. Treatment of Jurkat cells with MTX or adenosine did not change 
expression levels of these JUN family members. Culture with MTX or 
adenosine did not affect cell numbers or viability, as determined 
microscopically. Thus, exposure to MTX, but not adenosine, directly increased 
JUN expression levels in a uniform T cell population but did not change 
expression levels of the Jun family members, JUNB and JUND.  
 Because the transcription factor activator protein 1 (AP-1) is a 
heterodimer composed of a Jun family member and a Fos family member109, 
we determined the impact of MTX treatment on levels of Fos family member 
transcripts. Similar to what was observed for JUN, FOS messenger RNA 
(mRNA) expression levels increased in Jurkat cells after stimulation by MTX 
(Figure 2-3C). In contrast, stimulation by adenosine did not alter FOS mRNA 
expression (Figure 2-3D). We examined changes in the mRNA levels of 
additional FOS family members FOSL1 and FOSB. We did not detect 
changes in transcript levels of these 2 genes following exposure to MTX or 
adenosine. The kinetics of FOS induction were different from the kinetics of 
JUN induction following MTX stimulation. FOS mRNA levels reached a peak 
after 24-48 hours, depending on the concentration of MTX, and declined by 72 
hours, whereas JUN mRNA levels reached a peak at 72 hours. Taken 
together, these results demonstrated that MTX induced increased expression 
of both the JUN and FOS components of the AP-1 transcriptional complex in 
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Jurkat cells. They also showed that MTX specifically induced JUN and FOS 
mRNA but not mRNA encoding other Jun and Fos family members.  
 As an alternate approach, we sought to determine whether the 
adenosine receptor antagonists with broad specificity, caffeine and/or 
theophylline, interfered with the induction of JUN and FOS mRNA. Caffeine, 
theophylline, or their combination, at pharmacologically active 
concentrations, did not interfere with the induction of JUN and FOS mRNA. 
Caffeine, theophylline, or their combination, at pharmacologically active 
concentrations, did not interfere with the induction of JUN and FOS mRNA 
by MTX (Figure 2-3E and 2-3F). Taken together, these results do not provide 
evidence against the notion that the anti-inflammatory effects of MTX may 
be mediated, in part, via stimulation of adenosine release and activation of 
adenosine receptors. Rather, the results presented here clearly demonstrated 
that adenosine alone is not sufficient to increase the expression of FOS and 
JUN mRNA in T cells, and that adenosine receptor antagonists with broad 
specificity do not interfere with the induction of FOS and JUN mRNA by 
MTX.  
Blockade of MTX-induced apoptosis by free radical scavengers 
and tetrahydrobiopterin (BH4). MTX, at concentrations similar to those 
inducing JUN and FOS expression, leads to the production of ROS and 
priming for apoptosis.24  Furthermore, ROS are known to activate JNK, 
leading to increased JUN expression.101,110,111 We cultured Jurkat cells with 
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MTX and the free radical scavenger N-acetyl-L-cysteine (NAC) and examined 
changes in apoptosis sensitivity and JUN expression levels. The addition of 
NAC inhibited MTX-mediated changes in apoptosis sensitivity (Figure 2-4A) 
and MTX-mediated increases in JUN expression in Jurkat cells but did not 
alter baseline JUN levels (Figure 2-4B). Therefore, we attempted to 
determine whether MTX increased the production of ROS, using flow 
cytometry after labeling cells with CM-H2DCFDA. MTX caused a marked 
increase in ROS production (Figure 2-4C) that was effectively reduced by 
NAC (Figure 2-4D). We concluded that the JNK-dependent increases in 
apoptosis sensitivity and JUN transcript levels induced by MTX were 
mediated, at least in part, through ROS production. MTX inhibits the 
reduction of dihydrofolate to tetrahydrofolate and the reduction of 
dihydrobiopterin (BH2) to BH4 catalyzed by DHFR.112-114 BH4 is a necessary 
cofactor for nitric oxide synthases (NOS) including endothelial NOS (eNOS), 
which is expressed in T lymphocytes.115,116  The loss of BH4 uncouples eNOS 
from NO synthesis, leading to excess production of ROS. Thus, we tested 
whether supplementation with BH4 could reverse MTX-mediated increased 
apoptosis and ROS production. We observed that BH4 supplementation 
effectively reduced MTX-dependent apoptosis (Figure 2-4E), and MTX-
dependent increased ROS production (Figure 2-4F).  
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Figure 2-4. Free radical scavengers or tetrahydrobiopterin (BH4) 
supplementation blocks methotrexate (MTX)-mediated increases in apoptosis 
sensitivity. A and B, Jurkat cells were cultured for 48 hours with MTX and/or the free 
radical scavenger N-acetyl-L-cysteine (NAC), stimulated with anti-Fas for 6 hours, and 
the percentage of annexin-V-positive cells was determined (A) or the cultures were 
harvested and processed, and the jun transcript levels were determined (B). C and D, 
Jurkat cells were treated for 48 hours with MTX alone (C) or with MTX in the presence 
or absence of NAC, and reactive oxygen species (ROS) production was determined by 
labeling cells with CM-H2DCFDA. E and F, Jurkat cells were cultured for 48 hours 
with MTX (0.1 μM) with or without BH4 supplementation (30 μM). The percentage of 
annexin V-positive cells after anti-Fas treatment was determined by flow cytometry 
(E), and ROS levels were determined after loading Jurkat cells with CM-H2DCFDA. 
Bars show the mean ± SD. * = P < 0.05 versus unstimulated cultures; ** = P < 0.05 
versus MTX- and NAC-treated cultures (A and D) or MTX- and BH4-treated cultures (E 
and F).  
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These results are consistent with a model whereby inhibition of DHFR by 
MTX reduces intracellular levels of BH4, resulting in NOS-catalyzed ROS 
overproduction, leading to activation of JNK and increased apoptosis 
sensitivity.  
 Induction of JNK expression and activity by MTX. Inhibition of 
MTX-mediated increased JUN expression, priming for apoptosis, and 
expression of genes whose protein products are proapoptotic, by JNK 
inhibitors and by JNK1- and JNK2-DN mutants, suggest that MTX may 
increase JNK expression or activity. JNK is a member of the MAP kinase 
family and is activated by phosphorylation on threonine and tyrosine 
residues by JNK kinases, also termed MAP kinase kinases, in response to an 
array of stimuli.117,118 There are 3 JNK genes that produce multiple mRNA 
and protein isoforms. We used Western blotting to determine whether 
stimulation by MTX changed JNK1 total protein levels and phosphorylated 
JNK1/2 levels. Jurkat cells were cultured with different concentrations of 
MTX for 2 days. Whole cell lysates were prepared and analyzed by SDS-
PAGE and Western blotting with antibodies specific for JNK1 total protein or 
antibodies specific for the phosphorylated forms of JNK1 and JNK2. 
Culturing cells with MTX resulted in an increase in total JNK1 protein levels 
and levels of phosphorylated JNK1/2 (Figure 2-5A).  
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Figure 6.  MTX induces increased levels of JNK and phosphorylated [P]-JNK.  Jurkat T cells [A] or 
human PBMC [B] were treated with the indicated concentrations of MTX.  After 48 hrs, cells were 
harvested, whole cell lysates prepared and JNK 1 and P-JNK levels determined by western blotting with 
specific antibodies for either JNK 1 or P-JNK [1/2]. [C] Jurkat cells and [D] PBMC were treated with or 
without the indicated concentrations of MTX, labeled with specific antibodies for P-JNK or JNK and 
analyzed by flow cytometry.  Results are expressed as the mean fluorescence intensity above isotype 
control ± S.D.  * P < 0.05 relative to untreated Jurkat cells or PBMC. 
Jurkat 
--   10-8  10-7 10-6 MTX: --   10-8  10-7 10-6 MTX: 
JNK1 
P-JNK (1,2) 
JNK1 
P-JNK (1,2) 
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Figure 2-5. Methotrexate (MTX) induces increased levels of JNK and p-JNK. A and 
B, Jurkat T cells (A) or human peripheral blood mononuclear cells (PBMCs) (B) were treated 
with the indicated concentrations of MTX. After 48 hours, cells were harvested, whole cell 
lysates were prepared, and JNK1 and p-JNK levels were determined by Western blotting 
with specific antibodies for either JNK1 or p-JNK1/2. C and D, Jurkat cells (C) and PBMCs 
(D) were treated with or without MTX, labeled with specific antibodies for p-JNK or JNK, 
and analyzed by flow cytometry.  Bars show the mean ± SD mean fluorescence intensity 
(MFI). * = P < 0.05 versus untreated cells.  
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 We also cultured human PBMC with MTX for 2 days and analyzed 
whole cell lysates by SDS-PAGE and Western blotting. Similar to what was 
observed in Jurkat cells, culturing PBMCs with MTX resulted in 
concentration-dependent increases in total JNK1 protein and phosphorylated 
JNK1/2 (Figure 2-5B). We also examined changes in total phosphorylated 
JNK and total JNK levels by flow cytometry. These experiments confirmed 
changes in phosphorylated JNK and total JNK levels in Jurkat cells (Figure 
2-5C) and PBMCs (Figure 2-5D) following MTX treatment. We concluded that 
MTX induced an increase in the cellular levels of phosphorylated JNK 
protein and total JNK protein in both Jurkat cells and human PBMCs.  
JUN expression in RA patients receiving MTX. Given that MTX 
increased p-JNK levels in both Jurkat cells and PBMCs and expression of the 
known JNK target gene, JUN, we sought evidence for similar effects of MTX 
in vivo. To test this hypothesis, we determined expression levels of JUN in 
control subjects relative to patients with RA who were or were not currently 
receiving low-dose weekly MTX therapy. Blood samples were collected in 
PAXgene tubes. The expression levels of target genes were determined 
relative to GAPDH. We observed increased expression of JUN in the blood of 
patients with RA who were currently receiving MTX therapy relative to 
patients who were not receiving MTX therapy and control subjects (Figure 2-
6, far left).  
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Figure 2-6. Expression levels of the JNK target gene JUN in vivo in patients with 
rheumatoid arthritis (RA) as a function of current methotrexate (MTX) therapy. Blood 
was obtained in PAXgene tubes from control subjects (CTRL; n = 36), patients with RA not 
receiving MTX (RA – MTX; n = 28), and patients with RA receiving MTX (RA + MTX; n = 22). 
Bars show the mean ± SD gene expression levels relative to GAPDH. P values are versus control. 
NS = not significant.  
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In contrast, expression levels of 3 other genes, GNB5, TXK, and NRAS, were 
reduced in patients with RA compared with control subjects, independent of 
MTX therapy (or other therapies). We concluded that low-dose MTX therapy 
increased expression levels of JUN in whole blood, while the expression levels 
of other target genes that are reduced in patients with RA did not change in 
response to MTX therapy.  
 
Discussion 
 
 MTX was developed in the 1940's as an antagonist of DHFR, and since 
that time, the therapeutic efficacy of MTX has been attributed to inhibiting 
reduction of dihydrofolate to tetrahydrofolate resulting in inhibition of purine 
synthesis necessary for DNA and RNA synthesis.9,91  However, folate 
supplementation does not interfere with anti-inflammatory effects of MTX 
suggesting the presence of additional mechanisms of action of low-dose MTX 
for treatment of this class of disease.119  In the 1990's, it was proposed that 
production of adenosine, as a by-product of DHFR inhibition, stimulates 
adenosine receptors, thus contributing to the anti-inflammatory effects of 
MTX.13,36 An additional possible mechanism by which MTX may exert its 
anti-inflammatory effects is by induction of apoptosis of inflammatory cells, 
such as lymphocytes, yet it is not immediately apparent how these 
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biochemical pathways, which are activated or inhibited by MTX, may induce 
apoptosis.   
Our new model suggests that MTX inhibits DHFR-catalyzed BH2 
reduction to BH4.  The downstream biochemical effector pathways stimulated 
by loss of BH4 lead to altered cell sensitivity to apoptosis, thus shifting the 
decades-long focus of MTX action away from inhibition of dihydrofolate 
reduction to inhibition of BH2 reduction to BH4 [Supplementary Fig. 2-2].  
Our results support a model whereby submicromolar concentrations of 
methotrexate stimulate increased sensitivity to apoptosis via the death 
receptor and mitochondrial pathways.  Increased apoptosis sensitivity 
depends upon increased expression and activity of JNK and subsequent 
increased expression of JNK target genes.  JNK target genes include those 
whose protein products increase sensitivity of cells to apoptosis.  JNK 
activation is mediated in part by ROS, which we propose is induced by MTX-
dependent depletion of BH4 levels uncoupling eNOS from NO synthesis, 
resulting in overproduction of ROS.  Specific JNK inhibitors prevent both 
MTX-mediated effects on gene and protein induction and changes in 
sensitivity to apoptosis.   Both JNK1-DN and JNK2-DN mutants interfere 
with these MTX-mediated effects.  Thus, both JNK enzymes contribute to 
MTX-mediated changes in the transcriptional program in Jurkat cells and to 
alterations in sensitivity to apoptosis by regulating expression of different 
target genes.  Furthermore, patients with RA receiving low-dose weekly MTX 
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exhibit increased expression of JUN, the prototypical JNK target gene, thus, 
supporting the notion that this pathway is activated by MTX in vivo and may 
contribute to efficacy of MTX in inflammatory disease.  
 It is well established that JNK enzymes play both positive and 
negative roles in both death receptor and mitochondrial pathways of 
apoptosis.104  These roles can be mediated via JNK translocation to the 
nucleus and phosphorylation of transcription factors.  c-Jun is the 
prototypical transcription factor phosphorylated by JNK, but JNK also 
phosphorylates additional Jun family members, ATF and Elk family 
members, p53, c-Myc and others.120  JNK can also translocate to 
mitochondria and regulate activity of proteins involved in apoptosis, such as 
BAD, Bim, and 14-3-3, via phosphorylation.  In large part, these studies have 
examined roles of JNK in stimulating or preventing apoptosis in response to 
either external or internal stimuli.  Our results support a new role for JNK in 
regulating apoptosis.  The treatment of Jurkat T cells with MTX induces 
increased expression and activity of JNK, increased expression of JUN 
mRNA, and increased expression of a number of genes whose protein 
products are proapoptotic. However, MTX does not directly stimulate 
apoptosis under these conditions.  Rather, MTX-treated Jurkat cells are 
'primed' to exhibit markedly increased sensitivity to apoptosis when exposed 
to stimuli activating death receptor and mitochondrial pathways via a JNK-
mediated pathway.  Further experimentation will be required to address 
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whether JNK also 'primes' Jurkat cells for apoptosis by modulating activity of 
proapoptotic or antiapoptotic proteins via direct phosphorylation.  
In many cell types, activation of JNK is mediated by its 
phosphorylation in response to stimuli, including cellular stress and 
inflammatory cytokines.  In contrast, T lymphocytes exhibit a second level of 
regulation.  Resting or naïve T lymphocytes express low quantities of JNK 
enzymes.121  Activation via T cell receptor ligation leads to markedly 
increased expression of JNK genes and protein, whereas JNK 
phosphorylation requires CD28-mediated co-stimulatory signals.  Our results 
demonstrate that MTX treatment of Jurkat cells or human PBMC (70% T 
lymphocytes) leads to increased levels of phosphorylated JNK and total JNK 
protein.  Whether MTX treatment of non-T cells or non-lymphoid cells 
induces increased levels of phosphorylated JNK and total JNK protein 
remains to be determined.   
 The potential of JNK inhibitors as therapeutics for inflammatory 
disease has also attracted considerable interest.104,117,122-126 Modulation of 
JNK enzymes, either by genetic means or with small molecule inhibitors, 
interferes with a number of processes linked to inflammatory disease.  For 
example, many genes linked to inflammation, such as those encoding TNF-α, 
matrix metalloproteinases, and adhesion molecules, possess AP-1-response 
elements in their promoters and are regulated by JNK enzymes through 
activation of AP-1 and ATF-2 transcription factors.   Our results suggest a 
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second paradigm shift.  Our model suggests that correctly targeted activation 
of JNK, rather than its inhibition, represents a therapeutic goal for the 
treatment of inflammatory disease, especially RA.  In lymphocytes, increased 
JNK activity and subsequent increased sensitivity to apoptosis may also have 
therapeutic benefits in inflammatory diseases that are dependent upon T 
lymphocyte function by eliminating self-reactive T cells.  For example, 
activated T cells undergo apoptosis if exposed to secondary T cell receptor 
ligation in a process termed activation-induced cell death.95   
We speculate that MTX therapy may 'prime' self-reactive T cells to 
undergo increased activation-induced cell death in response to secondary 
exposure to self-antigen and thus produce its therapeutic benefit.  Future 
studies will be required to determine if this novel MTX-induced pathway can 
be exploited for therapeutic benefit.   
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CHAPTER III 
 
METHOTREXATE INCREASES EXPRESSION OF CELL CYCLE 
CHECKPOINTS GENES VIA JNK ACTIVATION 
 
Abstract 
Objective. To assess defects in expression of critical cell cycle 
checkpoint genes and proteins in subjects with rheumatoid arthritis (RA) 
relative to presence or absence of methotrexate medication and assess the 
role of Jun N-terminal kinase in methotrexate induction of these genes.  
Methods. Flow cytometry analysis was used to quantify changes in 
intracellular proteins, measure reactive oxygen species (ROS), and determine 
apoptosis in different lymphoid populations. Quantitative reverse 
transcriptase polymerase chain reaction (Q-RT-PCR) was employed to 
determine changes in cell cycle checkpoint target genes. 
 Results. RA subjects express lower baseline levels of MAPK9, TP53, 
CDKN1A, CDKN1B, CHEK2, and RANGAP1 messenger RNA (mRNA) and 
total JNK protein.  MAPK9, TP53, CDKN1A, and CDKN1B mRNA 
expression, but not CHEK2, and RANGAP1, is higher in patients on low-dose 
MTX therapy.  Further, JNK levels inversely correlate with CRP levels in RA 
patients.  In tissue culture, MTX induces expression of both p53 and p21 by 
JNK2 and JNK1-dependent mechanisms, respectively, while CHEK2 and 
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RANGAP1 are not induced by MTX.  MTX also induces ROS production, JNK 
activation, and sensitivity to apoptosis in activated T cells. Supplementation 
with tetrahydrobiopterin blocks these MTX-mediated effects.  
 Conclusions. Our findings support the notion that MTX restores 
some, but not all of the proteins contributing to cell cycle checkpoint 
deficiencies in RA T cells by a JNK-dependent pathway.  
 
Introduction 
 
Rheumatoid arthritis is the most common serious autoimmune disease 
affecting ~1.3 million people in the United States.127 Often characterized by 
bone erosion and cartilage destruction through chronic inflammation, RA is a 
multisystem disorder affecting synovial spaces between small and large 
joints. It accounts for ~250,000 hospitalizations and ~9 million clinic visits 
each year, and its associated costs represent approximately ~1% of the U.S. 
gross domestic product.128  
Though initially developed as a chemotherapeutic agent, methotrexate 
(MTX) has been the mainstay for RA treatment since the 1980s.3,9,11,28,90  
Once-weekly administration of 7.5-25 mg yields optimal clinical outcomes in 
RA, compared to the 5,000 mg/week dosage used in the treatment of 
malignancy.3,25 MTX is a potent, competitive inhibitor of dihydrofolate 
reductase (DHFR)6,87,88 resulting in decreased tetrahydrofolate levels, and 
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inhibition of de novo purine and pyrimidine synthesis, leading to cell cycle 
arrest.25,34  However, mechanisms of action surrounding low-dose, once 
weekly MTX may differ significantly from high dose therapy with MTX.  
Since supplementation with low doses of folic acid, (1-5 mg/day) does not 
attenuate clinical efficacy of MTX, the anti-inflammatory actions of low-dose 
MTX may stem from alternative pathways.25,36,119  
 Although the etiology of RA is incompletely understood, T lymphocytes 
from subjects with RA exhibit loss of genomic integrity and deficiencies in 
specific proteins that repair DNA damage and induce cell cycle arrest and 
apoptosis. Specifically, reduced expression of ataxia telangiectasia (AT) 
mutated (ATM), a critical component of DNA damage repair and activation of 
p53-dependent cell cycle arrest and apoptosis, p53 itself, checkpoint kinase 2, 
which also phosphorylates p53, and cyclin kinase inhibitors, p21 and p27, 
contribute to these defects in RA.18,84,129-131  
We recently found that Jun-N-terminal kinase (JNK), a MAP kinase, is 
activated by MTX through production of reactive oxygen species (ROS) due to 
uncoupling of nitric oxide synthase (NOS) arising from MTX-dependent 
inhibition of DHFR, which blocks reduction of dihydrobiopterin (BH2) to 
tetrahydrobiopterin (BH4). MTX-mediated JNK activation results in 
induction of pro-apoptotic target genes and increased sensitivity to 
apoptosis.132 Since JNKs, members of the MAP kinase family of proteins, also 
directly phosphorylate p53 leading to its increased accumulation and 
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activity133-135 we hypothesized that JNKs, or MAPKs in general, may also be 
deficient in RA and that MTX therapy may correct, not only JNK deficiency, 
but also deficiencies in critical regulators of cell cycle checkpoints.  Here, we 
show that RA lymphocytes exhibit a selective deficiency in MAPK9 (JNK2), 
but not other MAPK transcripts.  MAPK9, TP53, CDKN1A, and CDKN1B 
transcript levels, along with total JNK protein levels, are significantly lower 
in RA subjects compared to healthy control subjects (CTRL).  Further, 
MAPK9, TP53, CDKN1A, and CDKN1B transcript levels, but not CHEK2 and 
RANGAP1, are elevated in RA subjects taking MTX compared to RA subjects 
not taking MTX.  In cell culture models, MTX directly induces increased 
expression of p53, p21, and p27, but not CHEK2 and RANGAP1.  We 
hypothesize that therapeutic activity of MTX may arise, in part, from its 
ability to restore expression levels of key proteins required for cell cycle 
checkpoint arrest and that defects in the cell cycle and DNA damage-
response pathway may not only contribute to disease pathogenesis but may 
also serve as important markers of RA disease progression and may 
represent novel therapeutic targets for disease management. 
 
 
 
 
 
 55 
Materials and Methods 
 
 Patient Populations. Our study group contained 43 CTRL subjects 
with no current chronic or acute infection and no family history of 
autoimmune disease, and 36 subjects meeting the American College of 
Rheumatology (ACR) clinical criteria for RA.136 Demographic characteristics 
of the different disease and therapy groups were not statistically different 
(Supplementary Table 3-1).  Blood samples were also obtained from subjects 
with the following autoimmune diseases: multiple sclerosis (MS), ulcerative 
colitis (UC), Crohn’s disease, and systemic lupus erythematosus (SLE).  
These samples were collected from three different sites in the U.S.  Age, race 
and gender were not statistically different among the study groups.  Relevant 
institutional review board approval from all participating sites was obtained.  
 Drugs and Reagents. MTX, BH4, caffeine, theophylline, folic acid, 
and N-acetyl-L-cysteine (NAC) were from Sigma. CM-H2DCFDA was 
obtained from Invitrogen.  
 Cell Culture. Cells were cultured in RPMI 1640 media (1 µg/ml folic 
acid) supplemented with 10% (V/V) FBS, 1% (V/V) penicillin-streptomycin, 
and 1% (V/V) L-glutamine at 37°C in 5% CO2. The Jurkat human T cell line 
was obtained from the American Type Culture Collection (ATCC). Peripheral 
blood mononuclear cells (PBMC) were purified by Ficoll-Hypaque 
centrifugation or by using a cell preparation tube with sodium heparin 
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following the manufacturer’s published protocol (BD Biosciences #362753).  
For T cell activation, PBMC were cultured for 72 hours with anti-CD3 
antibody (OKT3 Clone ATCC) in complete media containing 30 units/mL 
interleukin-2 (IL-2). Concentrations of MTX ranged from 0.1µM to 1µM, and 
culture periods ranged from 24 hours to 48 hours of continuous exposure to 
MTX. Pharmacokinetic analysis indicates that ingestion of a 20-mg tablet of 
MTX produces plasma MTX concentrations of ~0.5µM after 1 hour and ~0.1 
µM after 10 hours.137  
 RNA isolation and quantitative real time polymerase chain 
reaction (Q-RT-PCR). Total RNA was purified from blood collected in 
PAXgene tubes according to manufacturer’s instructions (Qiagen) or from cell 
cultures using Tri-Reagent (Molecular Research Center) and quantified using 
a NanoDrop-1000 spectrophotometer. cDNA was synthesized from 5 µg total 
RNA (SuperScript III First-Strand Synthesis Kit, Invitrogen) with Oligo dT 
as the primer. Q-RT-PCR reactions were prepared in duplicate in volumes of 
25 µL with 50ng cDNA, TaqMan assay mix, and TaqMan gene expression 
assay. GAPDH was used as a housekeeping gene and control. Q-RT-PCR was 
performed using the ABI-7300 Real Time PCR System (Applied Biosystems).  
 C reactive protein (CRP) & JNK assay. Whole blood samples were 
obtained from RA subjects. From these blood samples, PBMC were isolated 
via Ficoll-Hypaque centrifugation. Isolated PBMC were fixed and 
permeabilized prior to flow cytometry analysis to quantify total JNK protein 
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levels, ex vivo. Plasma from each blood sample was retained for CRP analysis 
via enzyme linked immunosorbent assay (ELISA) following the 
manufacturer’s supplied protocol (R&D Systems).  
 Flow cytometry. Cells were suspended in PBS with 10% FBS and 
0.1% sodium azide.  For intracellular protein determinations, cells were fixed 
with paraformaldehyde, permeabilized (triton X-100 and NP-40) using 
Perm/Wash Buffer (BD Biosciences), and labeled with primary antibodies for 
24 hours at 0-4°C followed by incubation with fluorescent-labeled secondary 
antibodies for 1 hour at 0-4°C. The following primary antibodies were used: 
rabbit anti-JNK (Santa Cruz, sc-571), polyclonal rabbit anti-P-JNK 
(pT183/pY185) (BD Pharmingen 558268), polyclonal rabbit anti-p38 (Cell 
Signaling, 9212), polyclonal rabbit anti-p53 (Novus Biologicals, NB200-171), 
polyclonal rabbit anti-p21 (Abcam, ab7960); secondary antibodies: fluorescein 
isothiocyanate (FITC) – labeled goat anti-rabbit Ig (BD Pharmingen, 554020), 
and phycoerythrin (PE) - labeled goat anti-rabbit IgG (Southern Biotech, 
4050-09). The following surface stains were used: Pacific Blue mouse anti-
human CD4 (BD Pharmingen, 558116), Alexa Fluor 700 mouse anti-human 
CD8 (BD Pharmingen, 557945), and APC mouse anti-human CD19 (BD 
Pharmingen 555335). Apoptosis determinations utilized the PE Annexin-V 
Apoptosis Detection Kit I from BD Pharmingen. Cells were analyzed using a 
3-laser BD LSRII flow cytometer in the Vanderbilt Medical Center Flow Core 
or a BD FACSCantoII in the Hershey Medical Center Flow Cytometry Core.  
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 Plasmids and Cell transfection. JNK1 (MAPK8) and JNK2 
(MAPK9) dominant-negative (DN) mutants (Addgene) were transfected into 
Jurkat T Cells using the Amaxa Cell Line Nucleofector Kit V (Amaxa, Koeln, 
Germany) according to the manufacturer’s protocol.  
Statistical Analysis. Statistically significant differences between 
groups were determined by Student’s t-test. P values less than 0.05 were 
considered significant.  
 
Results 
 
Reduced MAPK9 expression, in vivo, in RA. Previously, we 
demonstrated that MTX stimulates increased JNK activity and expression 
levels in tissue culture models.132   Therefore, we sought to determine 
transcript levels of MAPK family members in RA and CTRL subjects by 
analyzing gene expression levels in subject blood samples collected in 
PAXgene tubes.  Expression levels, determined by Q-RT-PCR, were 
calculated as the ratio to GAPDH for normalization.  MAPK8 and MAPK9 
genes correspond to JNK1 and JNK2 proteins, respectively.  RA subjects 
exhibited significantly lower MAPK9 mRNA levels (Supplementary Table 3-
2). Transcript levels of other MAP Kinases, including genes encoding p38 and 
extracellular signal regulated kinase (ERKs) proteins, were not statistically 
different between the RA cohort and CTRL (Supplementary Table 3-2).  
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We next measured JNK expression levels by flow cytometry.  Total 
JNK protein levels in RA subjects not on MTX were diminished in CD4 and 
CD8 T cells, as well as CD19+ B cells relative to CTRL subjects (Fig. 3-1A).  
In contrast, p38 protein levels, another member of the MAP kinase family, 
often activated by a variety of different cellular stresses including 
inflammatory cytokines, UV exposure, and growth factors138,139, were not 
significantly different between the RA and CTRL cohorts in any of the 
lymphocyte subsets examined.   
JNK expression correlates with decreased C reactive protein, 
in vivo.  C reactive protein (CRP), found in plasma, is a common marker of 
inflammation often used during the treatment of rheumatoid arthritis to 
gauge disease activity or therapeutic efficacy.140,141 Building upon our 
findings that JNK levels are diminished in RA patients not on MTX, we 
sought to better understand the relationship between JNK and inflammation. 
Plasma and PBMC were isolated from RA patients not on current MTX 
therapy.  JNK levels were determined by flow cytometry and CRP levels were 
measured by ELISA (R&D Systems).  We found an inverse correlation 
between lymphocyte JNK levels and CRP concentrations, in vivo (Figure 3-
1B).   Thus, independent of MTX therapy, low JNK levels were associated 
with higher levels of inflammation and high JNK levels were associated with 
decreased levels of inflammation in RA.   
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Figure 3-1. MAPK9 (JNK-2) underexpression in rheumatoid arthritis (RA) is 
corrected by methotrexate (MTX) therapy. A, JNK total protein concentrations in 
RA patients (n = 18) and controls (n = 18) were determined by flow cytometry. Cells were 
fixed, permeabilized, and stained for CD4, CD8, and CD19 cell surface markers and 
intracellular proteins JNK and p38 using fluorescence-labeled secondary antibody. ∗ = P 
< 0.05 versus controls. B, The relationship between JNK expression levels and C-
reactive protein (CRP) levels was determined. Serum and peripheral blood mononuclear 
cells were isolated from RA patients (n = 7). Intracellular JNK levels were determined as 
described in A, and CRP levels were determined by enzyme-linked immunosorbent 
assay. Increased JNK expression correlated with decreased CRP levels in vivo. C, 
MAPK9 expression levels relative to expression of GAPDH were determined. Whole 
blood samples from control subjects (n = 43), RA patients not receiving MTX (RA − MTX) 
(n = 18), and RA patients receiving MTX (RA + MTX) (n = 18) were obtained in PAXgene 
tubes. D, MAPK9 levels in samples from patients with multiple sclerosis (MS) (n = 45), 
ulcerative colitis (UC) (n = 20), Crohn's disease (n = 23), and systemic lupus 
erythematosus (SLE) (n = 23) were determined as described in C. ∗∗∗ = P < 0.001 versus 
controls. Values in A (right panels), C, and D are the mean ± SD. ISO = isotype control; 
FITC = fluorescein isothiocyanate; MFI = mean fluorescence intensity. 
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MTX therapy restores MAPK9 expression levels, in vivo.  We 
next determined expression levels of MAPK9 in RA subjects on or not on 
current MTX therapy relative to CTRL subjects.  MAPK9 levels in RA 
subjects on MTX therapy were significantly higher than those without MTX 
(Figure 3-1C).  However, the mean MAPK9 expression level in the RA + MTX 
cohort was still lower than in the CTRL cohort. Given these results, we 
analyzed additional autoimmune diseases to determine if MAPK9 deficiency 
was unique to RA.  Among the diseases examined, multiple sclerosis (MS), a 
neurologic autoimmune disease, also exhibited decreased transcript levels of 
MAPK9 relative to CTRL (Figure 3-1D).  In contrast, subjects with the 
autoimmune diseases, ulcerative colitis (UC), Crohn’s, or systemic lupus 
erythematosus (SLE) did not exhibit decreased MAPK9 transcript levels.  
Thus, we conclude that MAPK9 deficiency exists in MS but is not a general 
feature of all human autoimmune diseases.  
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MTX therapy restores TP53, CDKN1A, and CDKN1B levels, in 
vivo.  We next examined expression levels of genes encoding proteins 
necessary for cell cycle checkpoint arrest including: TP53 (p53), CDKN1B 
(p27), CDKN1A (p21), CHEK2 (CHK2), and RANGAP1 (RANGAP1). 
Transcript levels of each gene were significantly under-expressed in 
lymphocytes from subjects with RA not on current MTX therapy (Figure 3-2). 
We compared expression levels of these additional genes in RA subjects on or 
not on current MTX therapy to expression levels of CTRL subjects.  As with 
MAPK9 deficiency, we found that TP53, CDKN1A, and CDKN1B levels were 
significantly increased in RA subjects on MTX therapy relative to those not 
on MTX, but levels were not restored to mean levels of the CTRL population. 
Transcript levels of CHEK2 and RANGAP1 were also decreased in RA 
subjects compared to CTRL. In contrast to expression levels of TP53, 
CDKN1A, and CDKN1B, there were no differences in transcript levels of 
either CHEK2 or RANGAP1 in the RA groups with or without MTX therapy.   
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Figure 3-2. Deficiencies in expression of genes encoding p53, p27, and p21 are 
restored by MTX in vivo. TP53, CDKN1B, CDKN1A, CHEK2, and RANGAP1 
transcript levels relative to GAPDH transcript levels in control subjects (n = 43), RA 
patients not receiving MTX (n = 18), and RA patients receiving MTX are shown. Values 
are the mean ± SD. NS = not significant (see Figure 1 for other definitions). 
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These studies suggest that MTX may restore deficiencies in expression of cell 
cycle checkpoint proteins, p53, p21, and p27, but not deficiencies in 
expression of cell cycle checkpoint proteins, CHK2 and RANGAP1.   
 Induction of TP53 and CDKN1A by MTX in Jurkat T cells.  
Given our findings that expression levels of TP53, CDKN1A, and CDKN1B, 
but not RANGAP1 or CHEK2, were elevated in RA subjects taking MTX 
compared to those not taking MTX, we sought to better understand 
mechanistic underpinnings of these differences. Previously we have shown 
that sub-micromolar concentrations of MTX induces transcription of JUN in 
a homogeneous T cell population (Jurkat T cells) by DHFR-dependent 
depletion of BH4 resulting in uncoupling of NOS and corresponding increased 
production of reactive oxygen species (ROS) and JNK activation.132 Therefore, 
we employed this model system to investigate MTX-induction of TP53, 
CDKN1A, RANGAP1 and CHEK2.  In these expression studies, we found 
that MTX directly stimulated an increase in transcript levels of TP53 and 
CDKN1A (Figure 3-3A).  In contrast, MTX did not significantly alter 
expression levels of CHEK2 and RANGAP1.  Since MTX stimulates 
adenosine release and activation of adenosine receptors, we determined if the 
broad-spectrum adenosine receptor antagonists, caffeine and theophylline, at 
pharmacologic concentrations, significantly altered the transcriptional profile 
of these genes. Treatment with caffeine, theophylline, or the combination, did 
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not alter induction of TP53 or CDKN1A transcripts by MTX (Figure 3-3B). In 
contrast, supplementation with either the free radical scavenger N-acetyl-L-
cysteine (NAC) or folic acid prevented induction of TP53 and CDKN1A by 
MTX (Figure. 3-3C). NAC supplementation of MTX-treated cultures prevents 
ROS production, JNK activation, and induction of JUN, a JNK target gene 
(20).  Folic acid, at very high concentrations (100 mM), also increases 
intracellular BH4 levels through its active form, 5-methyltetrahydrofolate, 
and restores the amount of available nitric oxide in the cell.142,143  We also 
treated Jurkat cells with MTX and assayed intracellular protein 
concentrations by flow cytometry. MTX treatment significantly increased 
levels of JNK, p-JNK, p53, and p21. Supplementation with BH4 significantly 
reduced expression of these proteins (Figure 3-3D).  MTX alters the 
transcriptional profile of cells by increasing expression of a number of genes 
that encode proteins with pro-apoptotic function.132  This shift depends upon 
ROS-stimulated phosphorylation of JNK.  Therefore, we performed transient 
transfection experiments with JNK1- and JNK2-DN mutants to determine if 
either JNK1 or JNK2 activity was necessary for MTX-mediated induction of 
p53 or p21.  We found that the JNK1 DN mutant reduced MTX dependent 
p21 expression while the JNK2 DN mutant decreased MTX-dependent p53 
expression (Figure 3-3E). Therefore, we conclude from these studies that 
induction of p53 by MTX is mediated by JNK2, whereas induction of p21 by 
MTX is mediated by JNK1.  
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Figure 3-3. Free radical scavengers, folic acid, and tetrahydrobiopterin (BH4) block 
MTX-mediated induction of p53 and p21 by JNK. A, JKT cells were cultured with MTX at 
0.1 µM or 1.0 µM for 48 hours. Target gene transcript levels were normalized to GAPDH and 
calculated as the fold increase relative to levels in untreated samples (set at 1). ∗ = P < 0.05 
versus unstimulated cultures. B and C, JKT cells were cultured with the adenosine receptor 
antagonists caffeine (CAFF) and/or theophylline (THEO) (B) or with N-acetyl-l-cysteine (NAC) or 
folic acid (C). Results are expressed as described in A. ∗ = P < 0.05 versus unstimulated cultures; ∗∗ = P < 0.05 versus cultures stimulated with MTX alone. D, JKT cells were cultured with MTX 
with or without BH4, and levels of JNK, p-JNK, p53, and p21 were determined by flow 
cytometry. Representative flow diagram shows background fluorescence (green) and results 
obtained with untreated cells (gray), MTX-treated cells (blue), and MTX plus BH4–treated cells 
(red). ∗ = P < 0.05 versus unstimulated cultures; ∗∗ = P < 0.05 versus cultures stimulated with 
MTX or BH4 alone. E, JNK-1–dominant-negative (DN), JNK-2–DN, or empty vector plasmids 
with green fluorescent protein (GFP) marker were transfected into JKT cells. Cells were 
cultured with MTX for 48 hours and assayed for p53 and p21 with gating on GFP-positive and -
negative cells. Results are representative of 3 experiments. ∗ = P < 0.05 versus unstimulated 
cultures; ∗∗ = P < 0.05 versus MTX alone or MTX and JNK-1–DN plasmid–transfected culture 
(p53), or versus MTX alone or MTX and JNK-2–DN plasmid–transfected culture (p21). Values 
are the mean ± SD. See Figure (3-1) for other definitions. 
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BH4 supplementation blocks MTX-mediated JNK induction, 
ROS production, and apoptosis priming in activated T cells.  MTX 
increases sensitivity of Jurkat cells to apoptosis by a JNK dependent 
pathway.132 Isolated PBMC were stimulated by anti-CD3 for 72 hours and 
treated with MTX (0.1µM) for an additional 24 hours. Cultures were 
supplemented with IL-2 to promote T cell proliferation.  Changes in apoptosis 
were determined by flow cytometry after labeling cells with Annexin-V.  
Mitogen-activated T cells exhibited slightly increased sensitivity to apoptosis 
in response to MTX alone, but this was enhanced by exposure to anti-Fas, 
similar to that observed in Jurkat cells (Figure 3-4A).  Supplementation of 
cell cultures with BH4 (30 mM) prevented MTX mediated increases in 
sensitivity to apoptosis.  Another form of apoptosis induced in activated T 
cells is via T cell receptor stimulation, often referred to as activation induced 
cell death (AICD).144  Activated T cells were cultured with MTX for 24 hours 
and re-stimulated with anti-CD3.  Apoptosis measurements by Annexin V 
labeling were performed after an additional one-day incubation.  Treatment 
with MTX markedly increased the level of AICD in activated T cells (Figure 
3-4B).  We also measured JNK expression levels in activated T cells treated 
with MTX by flow cytometry.  As in Jurkat cells, JNK expression levels were 
increased following stimulation by MTX (Figure 3-4C).  Increases in JNK 
levels were prevented by supplementation with BH4.   
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Figure 3-4. Tetrahydrobiopterin (BH4) reverses methotrexate (MTX)–mediated apoptosis 
priming, JNK activation, an  reactive oxygen species (ROS) pro uction in activated T 
cells. A, Activated peripheral blood mononuclear cells were treated ith 0.1 µM MTX for 24 hours 
with or without addition of BH4 (30 µM). After 24 hours, cultures were stimulated with anti-Fas for 6 
hours to induce apoptosis. ∗ = P < 0.05 versus unstimulated cultures; ∗∗ = P < 0.05 versus stimulation 
with MTX and anti-Fas without BH4. B, Activated T cells were treated with MTX for 24 hours and 
stimulated with anti-CD3 (secondary stimulation [Sec. Stim.]) for an additional 6 hours. ∗ = P < 0.05 
versus unstimulated and MTX-treated cultures. C, Activated T cells were cultured with MTX for 24 
hours with or without BH4 (30 µM) and assayed for JNK protein with gating on CD4+ T cells. ∗ = P < 
0.05 versus stimulation with MTX without BH4. D, Activated T cells were treated as described in C 
and then cultured with 5,6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate dye for 1 hour 
prior to flow cytometry. ROS production was measured with gating on the lymphocyte population, 
with measurements expressed as fluorescence relative to that obtained with untreated cultures 
without addition of BH4. ∗ = P < 0.05 versus unstimulated cultures. Values are the mean ± SD. 
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We also determined MTX stimulated ROS production in activated T cells by 
flow cytometry using the CM-H2DCFDA dye.  MTX induced ROS production 
in activated T cells (Figure 3-4D). ROS production by activated T cells was 
also inhibited by supplementation with BH4.  Our results support the notion 
that MTX inhibition of DHFR depletes intracellular stores of BH4 in 
activated T cells increasing ROS production leading to JNK activation and 
alteration in sensitivity to apoptosis.  Addition of BH4 reversed these 
methotrexate-mediated effects.  
 
Discussion 
 
 RA T cells exhibit functional defects in cell survival, DNA damage 
responses, and apoptosis.18,145-147 MAPKs also play key roles in these 
fundamental cellular processes148 and our recent work demonstrates that 
MTX, one of the most frequently prescribed pharmacologics in the 
management of RA, activates JNK and prototypical downstream targets, c-
JUN and c-FOS, components of the AP-1 complex and increases sensitivity of 
cells to apoptosis, raising the question of whether JNK or other MAPK 
deficiencies may exist in RA T cells.132  Our results demonstrate that MAPK9 
transcript levels, but not other MAPK transcripts, and JNK protein levels in 
lymphocytes, are markedly reduced in RA patients not on MTX therapy. RA 
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subjects treated with once weekly MTX, exhibit increased MAPK9 transcript 
levels relative to RA subjects not on MTX.   
 Transcript levels of other genes encoding proteins critical to DNA 
damage induced cell cycle checkpoint arrest, TP53, CDKN1A, CDKN1B, 
RANGAP1, and CHEK2, are also diminished in RA subjects.  Expression 
levels of TP53, CDKN1A, and, CDKN1B, but not CHEK2 or RANGAP1 are 
elevated relative to RA subjects not on MTX.  Our results are consistent with 
a model whereby defects are present at each checkpoint along the cell cycle; 
G1: CDKN1B (p27), S: CDKN1A (p21), G2: CHEK2 (CHK2), and M: 
RANGAP1 (RANGAP1)149-152 and that RA T cells respond to MTX therapy by 
restoring a portion, but not all of these cell cycle checkpoints (Figure 3-6). In 
a cell model, MTX induces protein expression of JNK and subsequent 
induction of p21 and p53 transcripts and protein through JNK1 and JNK2 
mediated pathways, respectively.  MTX fails to increase RANGAP1 and 
CHEK2 transcripts. Further, MTX stimulates activated T cells to increase 
ROS production, JNK protein levels, and to increase apoptosis sensitivity by 
a BH4 reversible mechanism. The general view is that checkpoints at each 
stage of the cell cycle exist to maintain fidelity of the genome through the 
process of DNA replication and cell division.  Loss of genomic integrity in 
hematopoietic cells in RA may arise from combined defects in DNA repair 
machinery, e.g. ATM, MRE11, NBS1, RAD50, and defects in expression of 
proteins required to establish each cell cycle checkpoint.   
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Figure 3-5. Summary model of cell cycle checkpoint gene expression 
deficiencies and methotrexate targets found in rheumatoid arthritis.  
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One hypothesis is that deficient DNA repair machinery exerts replicative 
stress upon T cells in RA increasing apoptosis and promoting proliferation 
and selection of autoreactive T cells in response to lymphopenia.145  Failure of 
cell cycle checkpoints may also contribute to RA by multiple mechanisms, 
including loss of immunologic tolerance to self-antigen, significant 
enhancement of T cell activation in response to external stimuli, or by 
maintenance of effector cells in a proliferative state for excessive periods of 
time.  Defects in cell cycle arrest may also produce a pro-inflammatory state.  
For example, loss of genomic integrity leads to activation of the transcription 
factor NF-kB via an ATM-dependent mechanism.153 Deficiencies in p53 may 
also contribute to NF-kB activation.154  Thus, these defects in cell cycle 
checkpoints and repair of DNA damage may be critical to establish and 
maintain the chronic inflammation responsible for much of the pathogenesis 
of RA.   
 Therapeutic efficacy of MTX may arise, in part, via its ability to restore 
JNK and p53 pathways leading to apoptosis of activated RA T cells in the 
face of pervasive DNA damage.  In addition, MTX may promote autoreactive 
T cells to undergo apoptosis upon secondary stimulation with self-antigen.  
Further, MTX treatment shifts the cytokine balance from a pro-inflammatory 
state to an anti-inflammatory state.  Depletion of BH4 in activated T cells via 
inhibition of guanosine triphosphate cyclohydrolase-1 (GTPCH-1), the rate 
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limiting enzyme in the synthesis of BH4, similarly shifts the cytokine balance 
from a pro-inflammatory to anti-inflammatory state by uncoupling iNOS.155  
Thus, MTX may exert multiple effects on T cells to reduce the inflammatory 
state in RA.   
 Synovial fibroblast-like cells or synoviocytes in RA also exhibit defects 
in p53 function and exhibit defects in cell cycle control. Synoviocytes also 
contribute to extracellular matrix destruction and joint and cartilage 
destruction in RA.15,86 Thus, MTX may also act on RA synoviocytes to restore 
p53 function and cell cycle control, thus reducing synovial hyperplasia and its 
manifestations.  Future studies are planned to test this hypothesis.  
Defects in cell cycle control and apoptosis play well-established roles in 
malignancy.  An emerging view is that defects in these pathways have 
broader ramifications for human disease.  For example, ATM-CHK2-p53 
defects also exist in lymphocytes from patients with MS that confer an 
inability to properly undergo apoptosis due to under-expression of ATM and 
impaired ability to stabilize p53, which may contribute to perpetuation and 
progression of this disease.156 Our finding of decreased MAPK9 mRNA 
expression in MS represents an additional connection between RA and MS.  
In the broad sense, defects in DNA damage responses have been linked to 
infertility, cardiovascular disease, and metabolic syndrome.157  Patients 
diagnosed with RA frequently suffer from inflammation-associated coronary 
artery atherosclerosis leading to increased mortality.158,159  
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MTX, the standard of care in the treatment of RA, restores a portion of 
these defects in cell cycle checkpoints and DNA damage responses in RA. 
However, as our data show, MTX still falls short in correcting the DNA 
damage response pathway and cell cycle checkpoint deficiencies to those of 
CTRL. These results highlight the need for additional pharmacologic agents 
to specifically target these additional cell cycle checkpoints.   
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CHAPTER IV 
 
METHOTREXATE-MEDIATED INHIBITION OF NF-κB ACTIVATION 
BY DISTINCT PATHWAYS IN T CELLS AND SYNOVIOCYTES 
 
Abstract 
 
Introduction. Methotrexate (MTX) is one of the most commonly 
prescribed disease-modifying anti-rheumatic drugs for the treatment of 
rheumatoid arthritis (RA). Despite decades-long experience with MTX, the 
precise mechanisms underlying its anti-inflammatory effects remain 
incompletely understood. NF-κB is a critical regulator of inflammatory 
processes. Therefore, we sought to investigate mechanisms of methotrexate-
mediated inhibition of NF-κB activation in lymphocytes and fibroblast-like 
synoviocytes.  
Methods. An NF-κB luciferase reporter plasmid was used to measure 
NF-κB activation across experimental stimuli. Western blotting and flow 
cytometry were used to quantify changes in intracellular protein levels. Flow 
cytometry was performed to determine levels of reactive oxygen species and 
of apoptosis.  Quantitative reverse transcription-polymerase chain reaction 
was used to identify changes in MTX target genes.  
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Results. In T cell lines, methotrexate (0.1 µM) inhibited activation of 
NF-κB via depletion of tetrahydrobiopterin and increased JNK-dependent 
p53 activity. Inhibitors of tetrahydrobiopterin activity or synthesis also 
inhibited NF-κB activation and, similar to methotrexate, increased JNK, p53, 
p21 and JUN activity.  Patients with rheumatoid arthritis expressed 
increased levels of phosphorylated or active RelA (p65) compared to controls. 
Levels of phosphorylated RelA were reduced in patients receiving low-dose 
methotrexate therapy. In contrast, inhibition of NF-κB activation by 
methotrexate was not mediated via BH4 depletion and JNK activation in 
synoviocytes but rather was completely prevented by adenosine receptor 
antagonists. 
Conclusions. Our findings support a model whereby distinct 
pathways are activated by methotrexate in lymphocytes and synoviocytes, 
respectively, to inhibit NF-κB activation. 
 
Introduction 
 
Rheumatoid arthritis (RA) is the most common, serious autoimmune 
disease affecting 1% of the world’s population.14 Methotrexate (MTX) is the 
standard of care for the treatment of RA, but the precise mechanism by which 
MTX exerts its anti-inflammatory effects remains incompletely understood. 
MTX was originally designed in the 1940s as a folic acid antagonist for the 
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treatment of malignancy. In cancer, folate antagonism via competitive 
inhibition of dihydrofolate reductase (DHFR) decreases de novo methyl 
donors tetrahydrofolate and methyltetrahydrofolate blocking purine and 
pyrimidine biosynthesis, effectively halting DNA replication and cell 
proliferation.11  It wasn’t until the late 1970s and early 1980s that MTX 
became widely used in RA, but it has since emerged as the basis by which all 
other therapies for RA are judged.3,28 At the time, it was inferred that the 
anti-inflammatory and immunomodulatory effects of MTX stem from a 
similar biochemical pathway. However, work spanning the last three decades 
has indicated that there is still much to learn about the functional role of 
MTX in the management of RA.  
MTX is polyglutamated once taken up by cells. MTX-polyglutamates 
are believed to represent its active form and levels of MTX-polyglutamates 
correlate with clinical efficacy in patients with RA.160 A prevailing theory has 
been that anti-inflammatory effects of MTX stem from inhibition of 
aminoimidazolecarboxamidoribonucleotide (AICAR) transformylase causing 
increased intracellular AICAR levels.  Increased AICAR levels inhibit 
adenosine monophosphate deaminase and adenosine deaminase leading to 
accumulation and release of adenosine and subsequent A2A and A3 
adenosine receptor activation producing anti-inflammatory 
properties.4,5,23,34,36,41,161  However, since folate supplementation does not 
reverse the anti-inflammatory effects of MTX, in vivo, the mechanism by 
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which MTX exerts its vulnerary effects in RA may stem from additional 
biochemical pathways.119  DHFR also catalyzes reduction of dihydrobiopterin 
(BH2) to tetrahydrobiopterin (BH4), which is inhibited by MTX 112-114,162.  BH4 
is a necessary cofactor of all nitric oxide synthases (NOS) and loss of BH4 
‘uncouples’ NOS leading to loss of NO synthesis and gain of reactive oxygen 
species (ROS) synthesis, such as H2O2.  MTX-mediated NOS ‘uncoupling’ and 
ROS production activates Jun-N-terminal kinase (JNK) and JNK-dependent 
induction of p53 and p21 and increased sensitivity to apoptosis via intrinsic 
and extrinsic pathways.  Subjects with RA exhibit reduced levels of JNK, p21 
and p53 in PBMC while subjects with RA receiving MTX possess normal 
levels of JNK, p21 and p53 in PBMC, suggesting that MTX-mediated 
inhibition of reduction of BH2 to BH4 also contributes to the therapeutic 
effects of MTX in RA, possibly by eliminating self-reactive T cells.132,163  
Excess TNF-α production plays a central role in RA pathogenesis as 
evidenced by efficacy of therapies that selectively reduce TNF-α levels, in 
vivo.  Activation of the transcription factor, NF-κB is a major cellular 
response to TNF-receptor signaling.164-166  MTX is also thought to reduce 
inflammation by lowering levels of TNF-α and/or NF-κB activity.167  However, 
mechanistically, it is not apparent if and how any of those pathways 
activated by concentrations of MTX achieved in vivo by standard low-dose 
therapy may inhibit NF-κB activity.  Further, it is unclear if different cells 
involved in RA pathogenesis, e.g. T lymphocytes, synoviocytes, respond to 
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MTX by activating a single common pathway or multiple pathways.  Since 
these pathways are similarly activated in both primary cells and cell lines, to 
address these questions, we determined if low concentrations of MTX 
inhibited NF-κB activation in tissue culture models in both Jurkat T 
lymphocytes and fibroblast-like synoviocytes (FLS) and in vivo in subjects 
with RA.  To do so, we employed an NF-κB reporter construct in cell-based 
assays and measured phosphorylation of RelA (p65) as an indicator of NF-κB 
activity, in vivo.  Our studies in Jurkat T cells demonstrate that MTX 
inhibits NF-κB activation via MTX-dependent depletion of BH4, increased 
ROS synthesis, and JNK and p53 activation. Further, we find that a BH4 
antagonist or inhibition of BH4 synthesis also stimulates JNK 
phosphorylation and induces p53 leading to decreased NF-κB activation. In 
vivo, RA PBMC exhibit elevated levels of phosphorylated p65 (p-p65) relative 
to control (CTRL) PBMC.  Levels of p-p65 are near those of CTRL PBMC in 
PBMC from RA subjects taking MTX.  In contrast to these results, MTX fails 
to induce ROS synthesis, JNK activation and downstream effects, apparently 
because synoviocytes express extremely low levels of NOS enzymes.  
However, MTX also inhibits NF-κB in synoviocytes, which appears dependent 
upon adenosine release and activation of A2A and A3 adenosine receptors.  
Our data are consistent with the notion that two independent pathways 
activated by MTX target two distinct cell lineages to produce anti-
inflammatory effects in RA. 
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Materials and Methods 
 
Drugs and Reagents. Methotrexate, (6R)-5,6,7,8-tetrahydrobiopterin 
dihydrochloride (BH4), caffeine, theophylline, BI-78D3, 2,4-diamino-6-
hydroxypyrimidine (DAHP), and (3-[4,5-Dimethylthiazol-2-yl]-2,5-
dipehyltetrazolium bromide) (MTT) were from Sigma-Aldrich (St. Louis, MO). 
4-amino-7, 8-dihydro-L-biopterin (4-ABH4) was from Schircks Laboratories 
(Jona, Switzerland). L-JNKi1 was from Enzo Life Sciences (Farmingdale, 
NY). Recombinant human tumor necrosis factor-alpha (TNF-α) was from 
Becton Dickinson (BD) Biosciences (Bedford, MA). The following primary 
antibodies were used: polyclonal rabbit anti-phospho-p65 (ab10684; Abcam, 
Cambridge, MA), polyclonal anti-phospho-JNK pT183/pY185 (558268; BD), 
polyclonal rabbit anti-p53 (NB200-171; Novus Biologicals, Littleton, CO), 
polyclonal rabbit anti-p21 (ab7960; Abcam), monoclonal mouse TRAILR1 
(ab18362; Abcam), and monoclonal rabbit anti-PUMA (ab33906; Abcam). 
Fluorescein isothiocyanate-conjugated goat anti-rabbit Ig (554020; BD) was 
used as secondary antibody. The NF-κB-luciferase reporter (NF-κB-luc) 
construct containing five κB elements was a gift from Dr. Dean W. Ballard 
(Vanderbilt, Nashville, TN). Jun-N-terminal kinase (JNK) – 1 and JNK-2 
dominant negative (DN) mutants were from the laboratory of Dr. Roger J. 
Davis (University of Massachusetts Medical School, Worcester, MA). The 
p53-DN construct was from the laboratory of Dr. William Kaelin, Jr. 
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(Harvard Medical School, Boston, MA). Plasmids were obtained from the 
Addgene repository.  
Cell culture. Cells were cultured in RPMI 1640 medium (1µg/mL folic 
acid) supplemented with fetal bovine serum (FBS) at 10% (volume/volume; 
Jurkat) or 20% (v/v; fibroblast-like synoviocytes, FLS), 1% (v/v) 
penicillin/streptomycin, and 1% (v/v) L-glutamine at 37°C in a humidified 
atmosphere of 5% CO2. Jurkat T cells were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA).  Fibroblast-like synoviocytes 
(FLS) from patients with RA were a generous gift from Dr. James W. Thomas 
(Vanderbilt, Nashville, TN).  
Transient transfections and luciferase measurements. Jurkat T 
cells were transfected using diethylaminoethyl (DEAE)-dextran.  Cells were 
incubated for 10 minutes at room temperature with 1µg NF-κB-luc construct 
per 1.0 x 106 cells in a solution of 0.5mg/mL DEAE-dextran in Tris-buffered 
saline. Cells were resuspended in complete RPMI 1640 culture medium with 
100µM chloroquine diphosphate and incubated at 37°C for 1 hour. 
Immediately following chloroquine treatment, cells were washed and 
resuspended in complete culture medium and incubated overnight prior to 
further experimental treatment. Synoviocytes were transfected using 
Lipofectamine-2000 (Life Technologies, Grand Island, NY) according to the 
manufacturer’s protocol.  Plasmid amounts were equalized across 
transfections. Luciferase was measured using Steady-Glo (E2510) from 
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Promega (Madison, WI) according to the manufacturer’s supplied protocol on 
a TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).  
RNA isolation, cDNA synthesis, and real-time PCR. Total RNA 
was isolated using Tri-Reagent (Molecular Research Center, Cincinati, OH), 
purified with the RNeasy MinElute Cleanup Kit (Qiagen, Germantown, MD), 
and quantified using a Nano Drop 1000 spectrophotometer. Complementary 
DNA (cDNA) was reverse transcribed from 5µg total RNA using the 
SuperScript III First-Strand Synthesis Kit (Life Technologies) using oligo(dT) 
as the primer and purified using the Qiagen QiaQuick PCR purification kit. 
Real-time qPCR (ABI-7300 Real Time PCR System; Applied Biosystems) was 
performed in duplicate using TaqMan gene expression assays in volumes of 
25µL with 50ng cDNA and TaqMan Gene Expression Master Mix.  Fold 
change expression levels were determined by the ΔΔCT method comparing 
expression of test genes to GAPDH.   
Flow Cytometry. Cells were suspended in phosphate buffered saline 
with 10% FBS and 0.1% sodium azide. For intracellular protein 
determinations, cells were fixed with BD Cytofix Buffer, permeabilized using 
BD Phospho Perm/Wash Buffer (BD Biosciences), and labeled with primary 
antibodies for 24 hours at 4°C followed by incubation with fluorescence-
labeled secondary antibodies for 1 hour at 4°C. Cells were analyzed using a 3-
laser BD LSRII flow cytometer at the Vanderbilt Medical Center Flow 
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Cytometry Core facility. Supplemental analysis was performed using FlowJo 
(Treestar, Ashland, OR).  
Study Populations. The study group consisted of 9 control subjects 
(age: 48 ± 8, 7 females, 2 males, 8 Caucasian, 1 African American) with no 
current chronic or acute infection and no family history of autoimmune 
disease, and 8 patients meeting the American College of 
Rheumatology/European League Against Rheumatism classification criteria 
for RA (age: 41 ± 12, 7 females, 1 male, 6 Caucasian, 2 African American). 
Demographic characteristics among control and disease cohorts did not differ 
significantly. The sample collection protocol was approved by the Vanderbilt 
University Human Research Protection Program and the Vanderbilt 
Institutional Review Board. Written informed consent was obtained at the 
time of blood draw.  
Western Blotting. Immunoblotting was performed as described 
previously 132. Briefly, peripheral blood mononuclear cells were isolated from 
whole blood using BD Vacutainer Cell Preparation Tubes.  Whole cell lystates 
were resolved by SDS polyacrylamide gel electrophoresis (PAGE) and 
transferred to polyvinylidene fluoride (PVDF) membranes overnight at 4°C. 
Membranes were washed and blocked using Odyssey Blocking Buffer (Li-
COR Biosciences, Lincoln, NE) for 1 hr at room temperature.  Membranes 
were thoroughly rinsed and incubated with primary antibodies overnight at 
4°C. Membranes were then washed and incubated with fluorescently labeled 
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IRDye 700/800 antibodies diluted in Odyssey blocking buffer in the dark. 
Blots were washed and resuspended in TBS prior to scanning and band 
quantification using the Li-COR Odyssey Infrared Imaging System (Li-COR 
Biosciences, Lincoln, NE).   
Statistical analysis. Data are expressed as the mean ± SD of three or 
more independent experiments.  Significance was determined by Student’s t-
test using GraphPad Prism Software (La Jolla, CA). P values < 0.05 were 
considered significant.  
 
Results 
 
Methotrexate reduces NF-κB activity in Jurkat cells.  
To determine the effects of MTX on NF-κB activation, an NF-κB 
reporter construct was transfected into Jurkat T cells.  Transfected cells were 
treated for 48 hours with 0.1µM MTX and stimulated with either phorbol 12-
myristate 13-acetate (PMA, 50nM) and ionomycin (1µM) or 5ng TNF-α for 24 
hours. We found that methotrexate markedly reduced stimulation of NF-κB 
activity in response to either PMA/ionomycin or TNF-α (Fig. 4-1 A).  MTX-
mediated inhibition of NF-κB activation by TNF-α was significantly reversed 
by supplementation of cultures with BH4, the free radical scavenger, N-acetyl 
cysteine (NAc), JNK inhibitors, BI-78D3 or L-JNKi1, or by transient 
transfection of JNK1-, JNK2-, or p53-dominant negative (DN) expression 
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vectors (Fig. 4-1 B).  JNK inhibitors BI-78D3 and pepJIP1 (L-JNKi1) target 
the JNK-JNK-interacting protein 1 (JIP1) binding site and prevent JNK 
phosphorylation.102,168 Consistent with our previous studies, we conclude that 
MTX-mediated inhibition of NF-κB activation by TNF-α resulted from MTX-
dependent BH4 depletion leading to increased ROS production, JNK 
activation and JNK-dependent induction of p53, which is the final mediator 
of inhibition of NF-κB activation. 
 We also tested the ability of folic and folinic acid to reverse MTX-
mediated inhibition of NF-κB activation by TNF-α.  Supplementation of 
cultures with either folic acid or folinic acid blocked inhibition of NF-κB 
activation by MTX (Fig. 4-1 C). BH2 and folate are converted to BH4 through 
a salvage pathway regulated by DHFR expression.169,170 Blockade of DHFR 
by MTX depletes tetrahydrofolate levels and decreases cellular amounts of 
BH4.  Supplementation of MTX-treated cultures with folic acid and/or folinic 
acid increases intracellular BH4 bioavailability.114  MTX also has been shown 
to stimulate the release of adenosine and activate adenosine (ADOR) 
receptors. Therefore, we examined the ability of two nonselective ADOR 
antagonists, caffeine and theophylline, to reverse the effects of MTX. 
Treatment of cells with MTX and either caffeine or theophylline alone at 
pharmacologic concentrations did not reverse MTX-mediated inhibition of 
NF-κB activation (Fig. 4-1 D).  
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Figure 4-1. Inhibition of NF-κB activation by MTX. A-D JKT cells containing an NF-κB-
luciferase reporter were cultured with 0.1 µM MTX for 48 hours and stimulated with PMA 
(50nM) and ionomycin (1µM) (A) or TNF-α (5ng) (A-D) 24 hours prior to luciferase 
measurements. B, MTX-treated JKT cells were cultured with or without BH4, N-acetyl-L-
cysteine (NAC), or JNK inhibitors, BI-78D3 or L-JNKi1. JNK1-DN, JNK2-DN, p53-DN or 
empty vector plasmids with a green fluorescent protein (GFP) plasmid were transiently 
transfected into JKT cells. C and D MTX-treated JKT cells were treated with folic or folinic 
acid (C) or adenosine receptor antagonists caffeine and/or theophylline (D). Values are the 
mean ± SD. A, * = p <0.05 versus PMA/ionomycin or TNF-α treated cultures. B-D, * = p < 0.05 
versus cultures stimulated with MTX alone.  
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However, incubation of cells with MTX and the combination of caffeine and 
theophylline significantly reduced inhibitory effects of MTX. We interpret 
these results to suggest that release of adenosine and ADOR activation also 
contributed to MTX-mediated inhibition of NF-κB activation.   
Induction of TP53, CDKN1A, and JUN by the 4-amino analogue 
of tetrahydrobiopterin.   
Given our findings that methotrexate inhibits NF-κB through blockade 
of tetrahydrobiopterin biosynthesis, we investigated if pterin-site inhibitors 
of NOS also inhibited NF-κB activation. One such inhibitor is 4-
aminotetrahydrobiopterin (4-ABH4). Jurkat cells treated for 48 hours with 4-
ABH4 show increased TP53, CDKN1A, and JUN expression levels and 
corresponding increases in phosphorylated JNK, p53, and p21 protein (Fig. 4-
2A & 4-2B) closely mirroring the stimulatory activity of MTX.  We also 
determined if 4-ABH4 inhibited TNF-dependent NF-κB activation in T cells. 
We found that 4-ABH4 decreased TNF-induced NF-κB activity to a level 
similar to MTX (Fig. 4-2 C). As an additional experimental comparator, we 
used diamino-hydroxypyrimidine (DAHP), which inhibits GTPCH-1 (GTP 
cyclohydrolase 1), the rate limiting enzyme in BH4 synthesis 155, and found 
that DAHP also significantly abrogated NF-κB activation.  Thus, both a BH4 
antagonist and an inhibitor of BH4 synthesis stimulated a pathway in T cells 
similar to that stimulated by MTX leading to inhibition of NF-κB by TNF-α 
activation. 
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Figure 4-2. Increased expression of p-JNK, p53, and p21, and inhibition of NF-κB 
activation by a BH4 anatagonist or an inhibitor of BH4 synthesis. A-C, Jurkat cells 
were treated with the BH4 antagonist, 4-ABH4 (200µM), for 48 hours and (A) transcript levels 
of TP53, CDKN1A, and JUN were measured by quantitative PCR.  Results are expressed as 
fold induction relative to GAPDH. B, Levels of p-JNK, p53, and p21 protein were determined 
by flow cytometry. A representative flow diagram shows background fluorescence (gray) and 
results obtained with untreated (solid line) or 4-ABH4 (dashed line) treated Jurkat cells. C, 
MTX, 4-ABH4, or DAHP treated Jurkat cells were stimulated with TNF-α for 24 hours prior to 
luciferase measurements. Results are expressed as % inhibition of TNF-α stimulated NF-κB 
activity in relative light units.  Values are the mean ± SD. * = p < 0.05 versus untreated cells.  
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Methotrexate corrects elevated p-p65 levels in RA subjects, in 
vivo.  
Since MTX reduced activation of NF-κB by TNF-α in T cells, we sought 
to examine the basal level of NF-κB activation in subjects with RA. For these 
studies, we prepared whole cell lysates from PBMC obtained from healthy 
control subjects and patients fulfilling the American College of 
Rheumatology/European League Against Rheumatism criteria for RA.  
Subjects with RA were divided into those receiving or not receiving MTX 
therapy.  Cell lysates were prepared and analyzed by SDS-PAGE and 
Western blotting using a specific p-p65 antibody. In control subjects, we 
found that p-p65 was essentially undetectable by western blotting (Fig. 4-3 A 
& 4-3 B).  In contrast, we detected increased p-p65 levels in RA subjects not 
receiving low-dose MTX as therapy. RA patients receiving once-weekly MTX 
exhibited decreased p-p65 levels, similar to controls. We conclude from these 
studies that RA subjects not receiving MTX exhibit chronic activation of NF-
κB compared to controls. Chronic activation of NF-κB is markedly reduced in 
RA subjects on stable MTX therapy. 
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Figure 4-3. Levels of p-p65 in PBMC from CTRL subjects or subjects with RA 
receiving or not receiving MTX therapy, in vivo. A. Whole cell lysates were prepared and 
p-p65 levels were determined by Western blotting in healthy control subjects (HC), and in RA 
patients receiving (RA+MTX) and not receiving MTX (RA-MTX). B Quantification of band 
intensities. Values are the mean ± SD. * = p < 0.05.  
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MTX-mediated inhibition of NF-κB activation in FLS. 
Both lymphocytes and fibroblast-like synoviocytes (FLS) are key effector cells 
in RA pathogenesis. Therefore, we determined if MTX also inhibited TNF-α 
mediated NF-κB activation low-passage FLS. FLS were transfected with the 
NF-κB luciferase reporter construct using lipofectamine and treated with 
0.1µM MTX for 48 hours.  As in T cells, MTX inhibited TNF-α dependent 
activation of NF-κB by about 50% (Fig. 4-4 A). However, in contrast to T cells, 
JNK inhibition did not attenuate inhibition of NF-κB activation by MTX.  In 
T cells, MTX induces cell cycle checkpoints and increases sensitivity to 
apoptosis via a JNK-dependent pathway 132,163. To examine these responses 
in FLS, we measured apoptosis by annexin-V labeling. FLS were treated with 
MTX for 48 hours and exposed to either anti-Fas or H2O2 for an additional 24 
hours as extrinsic or intrinsic mediators of apoptosis, respectively. In contrast 
to T cells, FLS did not exhibit increased levels of apoptosis after treatment 
with MTX followed by either anti-Fas or H2O2 (Fig. 4-4 B). Further, 
treatment of FLS with MTX or 4-ABH4 did not reduce cell number as 
measured by MTT assay (Fig. 4-4 C).  Levels of ROS or pro-apoptotic proteins 
as assessed by flow cytometry were also not increased in FLS by either MTX 
or 4A-BH4 (Fig. 4-4 D & 4-4E).  Finally, we performed mRNA measurements 
of low-passage or activated FLS and found that MTX or 4-ABH4 did not 
increase transcript levels of TP53, CDKN1A, or JUN, which is in marked 
contrast to T cells (Fig. 4-4 F, left panel). One possible explanation for the 
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failure of MTX to activate these ROS-JNK dependent pathways in FLS as is 
seen in both Jurkat and primary T cells is if FLS had significantly lower 
levels of NOS enzymes compared to T cells.   To test this possibility we 
compared NOS2 and NOS3 transcript levels among Jurkat T cells, primary 
activated T cells and FLS and found that Jurkat T cells and primary T cells 
expressed much higher NOS2 and NOS3 transcripts compared to FLS (Fig. 
4-4 F, right panel).  Thus, failure to activate these ROS-JNK dependent 
pathways in FLS is probably due to low levels of NOS enzymes in FLS thus 
preventing sufficient NOS-dependent ROS synthesis to activate JNK 
dependent pathways. 
Given these findings, we sought alternative explanations for decreased 
NF-κB activation in MTX-treated FLS.  Therefore, we examined effects of 
ADOR antagonists, caffeine and/or theophylline at pharmacologic 
concentrations. We found that the combination of caffeine and theophylline 
markedly abrogated inhibition of NF-κB activation by MTX (Fig. 4-4 G).  
Thus, in contrast to T cells, MTX appears to mediate inhibition of NF-κB 
activation in FLS by stimulating adenosine release.  
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Figure 4-4. Reversal of methotrexate-mediated inhibition of NF-κB activation by 
adenosine receptor antagonists in FLS. A-G FLS were treated with indicated 
concentrations of MTX or 4-ABH4 for 48 hours. A, FLS were transfected with an NF-κB 
luciferase reporter construct and treated with MTX ± BI-78D3. B, FLS were cultured with 
MTX followed by culture with anti-Fas antibody or H2O2 for an additional 6 hours. The 
percentage of annexin V-positive cells was determined by flow cytometry. C, FLS proliferation 
evaluated by MTT assay. D, Synthesis of ROS was determined by labeling FLS with CM-
H2DCFDA and flow cytometry.  E, Levels of JNK, p-JNK, p53, p21, PUMA, and TRAILR1 in 
MTX and 4A-BH4 treated FLS were determined by flow cytometry and are reported as the fold 
increase compared to untreated FLS. F, Transcript measurements of left panel: TP53, 
CDKN1A, and JUN in MTX or 4-ABH4 treated low-passage FLS or activated FLS stimulated 
with IL-1β (2ng/mL), TNF-α (50ng/mL) and LPS (1µg/mL) for 24 hours or right panel: NOS2 or 
NOS3 mRNA levels for the indicated cell type. G, FLS transiently transfected with an NF-κB 
luciferase reporter were treated with MTX ± adenosine receptor antagonists caffeine and/or 
theophylline for 48 hours and stimulated with TNF-α 24 hours prior to luciferase 
measurements. Values are the mean ± SD. A-F, * = p < 0.05 versus untreated FLS. G * = p 
<0.05 versus MTX treated FLS.  
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Discussion 
 
Our current studies coupled with previous studies indicate that MTX-
mediated inhibition of DHFR initiates two parallel anti-inflammatory 
pathways: (1) inhibition of BH2 reduction to BH4 leading to iNOS 
‘uncoupling’, ROS production, JNK activation and downstream effects and (2) 
AICAR-dependent adenosine release and activation of ADOR.  Both 
pathways ultimately lead to inhibition of stimulus-dependent activation of 
NF-κB, which most likely is a major contributor to the activity of MTX in RA.  
Interestingly, these two pathways seem to be activated in a cell-type specific 
manner.  The BH2/BH4 pathway seems to predominate in lymphocytes while 
the ADOR activation pathway is the predominant pathway in synoviocytes 
(Fig. 4-5).  A major difference between the two cell lineages is that 
synoviocytes express extremely low levels of NOS enzymes compared to T 
cells which probably explains failure to activate the BH2/BH4 pathway in 
synoviocytes. 
A BH4 antagonist or inhibition of BH4 synthesis also stimulates ROS 
production, JNK activation and downstream effector pathways similar to 
MTX.  In activated T cells, inhibition of BH4 synthesis also decreases 
production of the pro-inflammatory, TH1 associated cytokine, IFN-γ and 
increases production of the anti-inflammatory TH2 cytokine IL-4.155,171 MTX 
induces a similar shift and reduces expression of pro-inflammatory cytokines, 
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IL-1, IL-2, IL-6 and IFN-γ and increases expression of anti-inflammatory 
cytokines such as IL-4 and IL-10 in subjects with RA.172 Thus, we would 
argue that inhibition of BH4 synthesis by MTX might explain the pro-
inflammatory to anti-inflammatory shift found in RA.   
 
  
Figure 4-5. Summary model of MTX mediated inhibition of NF-κB 
activation in FLS and T cells.  
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Of particular interest is the association between MTX, p53, and NF-κB. 
While NF-κB governs cellular responses to external stimuli, p53, often 
referred to as the guardian of the genome, regulates endogenous or intrinsic 
processes eliminating cells with excess DNA damage through “cell cycle 
arrest, apoptosis, or senescence”.173  Together with NF-κB, these master 
regulators of internal and external stimuli must achieve a balance. Each 
transcription factor responds to a different form of cellular stress, adopting 
two very different strategies that have evolved into mutually exclusive 
processes.173 Importantly, NF-κB and p53 are known to have opposing 
functions. The interplay between these two factors and their response to 
therapy in RA has not been fully examined. In RA, defects in the p53 
pathway exist in both PBMC and synovium.15,18,86,174 Defects in these 
apoptosis and DNA damage control responses are blunted conferring genomic 
instability and aberrant cell function.85,175  We hypothesize that deficiencies 
in p53 in RA may also lead to increased activation of NF-κB, which we find in 
RA PBMC.  MTX acts to restore levels of p53 via JNK activation. Therefore, 
MTX may act to restore the balance between these two critical transcription 
factors, allowing clearance of damaged cells in the periphery of RA patients 
and reducing the chronic inflammation found in the joint spaces.  In fact, 
depressed levels of p53 in RA coupled with constitutive expression of NF-κB 
could elicit a pro-inflammatory cytokine loop that sustains disease 
pathogenesis.  
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Apart from RA, connections between p53 and NF-κB have been 
experimentally demonstrated in cancer models and in mouse endotoxemia.  
Overexpression of wild type p53 in human colon cancer cells reduces 
endogenous levels of NF-κB activity and restores the ability of these cells to 
undergo apoptosis.176  Further, glucocorticoids, which inhibit inflammation, 
block NF-κB activity through a p53 dependent process. Mortality from LPS-
induced endotoxemia, a process critically dependent upon NF-κB activity, is 
markedly increased in mice that lack p53.  The conclusion from these studies, 
closely mirroring our own work, is that p53 mediates repression of NF-κB.177  
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CHAPTER V 
METHOTREXATE INHIBITS NF-κB ACTIVITY VIA LINCRNA-P21 
INDUCTION 
 
Abstract 
 
Objective. We sought to determine interrelationships among 
expression of lincRNA-p21, a long intergenic non-coding RNA, activity of NF-
κB, and responses to methotrexate in rheumatoid arthritis (RA) by analyzing 
patient samples and cell culture models.   
Methods. Expression levels of long non-coding RNAs and messenger 
RNAs were determined by quantitative reverse transcription-polymerase 
chain reaction. Western blotting and flow cytometry were used to quantify 
levels of intracellular proteins. Intracellular NF-κB was determined using an 
NF-κB luciferase reporter plasmid.  
Results. RA patients expressed reduced basal levels of lincRNA-p21 
and increased basal levels of phosphorylated p65 (Rel A), a marker of NF-κB 
activation. RA subjects not receiving MTX expressed lower levels of lincRNA-
p21 and higher levels of phosphorylated p65 compared to RA subjects 
receiving low-dose MTX. Using a cell culture model, we found that MTX 
induced lincRNA-p21 through a DNA-PKcs-dependent mechanism. 
Deficiencies of PRKDC mRNA levels in RA subjects were also corrected by 
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MTX, in vivo. Further, MTX lowered NF-κB activity in TNF-α treated cells 
through a DNA-PKcs-dependent mechanism via induction of lincRNA-p21. 
Finally, we found that depressed levels of TP53 and lincRNA-p21 increased 
NF-κB activity in cell lines.  Decreased levels of lincRNA-p21 did not alter 
NFKB1 or RELA transcripts.  Rather, lincRNA-p21 physically bound to 
RELA mRNA.  
Conclusion. Our findings support a model whereby depressed levels 
of lincRNA-p21 in RA contribute to increased NF-κB activity.  MTX decreases 
basal levels of NF-κB activity by increasing lincRNA-p21 by a DNA-PKcs 
dependent mechanism.  
 
Introduction 
 
Rheumatoid arthritis (RA) is the most common autoimmune disease 
affecting more than one million adults in the United States.127 While the 
etiology of RA remains unknown, the disease is characterized by small and 
large joint erosion and disability that manifests across decades. Newer 
biologic therapies, such as those that inhibit activity of TNF-α, have 
enhanced the physician’s ability to improve outcomes and decrease 
disability.21  However, despite these advances, excess mortality observed in 
patients with RA continues and recent data suggest that the mortality gap 
between RA patients and the rest of the population continues to widen.20  
 100 
Although the origins of RA remain unknown, T cells in RA exhibit loss 
of genomic integrity via reduced expression of proteins responsible for cell 
cycle arrest and DNA damage repair.84,85 These include: reduced expression 
of sentinel DNA damage response proteins, ATM (ataxia telangiectasia 
mutated) and DNA-PKcs (DNA-protein kinase catalytic subunit), the tumor 
suppressor protein, p53, which is an ATM target protein, the cyclin-
dependent kinase inhibitors p21 and p27, and stress kinases, such as JNKs 
(c-Jun-N-terminal kinases) that also respond to DNA damage.77,84,146   
Genes that encode these proteins are also methotrexate (MTX) 
response genes.132,163 MTX is a potent inhibitor of dihydrofolate reductase 
(DHFR), which is classically thought to reduce purine and pyrimidine 
biosynthesis via depletion of tetrahydrofolate, thymidylic acid, and 
thymidylate synthase resulting in cell cycle arrest.34  Adenosine synthesis 
and activation of adenosine receptors may also contribute to anti-
inflammatory effects of MTX.3,23,36,41 Inhibition of DHFR by MTX also blocks 
reduction of dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4) leading to 
nitric oxide synthase (NOS) ‘uncoupling’ and production of reactive oxygen 
species (ROS). Increased ROS activates JNK increasing expression of p53 
and p21 via JNK-dependent mechanisms and enhances cellular apoptotic 
responses.132,163    
Effects of p53 are mediated in part by induction of the long non-coding 
RNAs (lncRNA), lincRNA-p21 and PANDA.178,179 LncRNAs represent a new 
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class of RNAs.  To date, 1,000’s of lncRNA genes have been identified in a 
mammalian genome.180,181 Genes encoding lncRNAs are similar to protein 
coding genes and contain exons and introns. Exons are spliced to produce 
mature lncRNAs.  However, unlike protein coding genes, lncRNAs do not 
code for proteins due to presence of multiple translational stop codons.181 One 
function of lncRNAs is to activate or repress transcription of protein-coding 
genes and thus lncRNAs play key roles in determining a cell’s transcriptional 
program.182  For example, lincRNA-p21 and PANDA play critical roles in 
mediating cellular responses to p53 activation.178,179 
Besides its role in apoptosis, p53 possesses anti-inflammatory 
properties demonstrated in tissue culture and animal models.183  In contrast, 
NF-κB is a transcription factor generally considered to exhibit pro-survival 
and pro-inflammatory properties.184  Thus, biologically, p53 and NF-κB may 
be considered to be antagonistic.173,185 However, it is unknown if p53 directly 
inhibits NF-κB activity and vice versa and how this inhibition may occur 
mechanistically.173,186  Here, we sought to explore the interrelationship 
between p53, its target lncRNAs, and NF-κB activity in the context of RA and 
MTX therapy.  We find that lincRNA-p21 is under-expressed in RA and MTX 
restores lincRNA-p21 levels to normal, in vivo.  Similarly, NF-κB activity is 
elevated in RA, in vivo, and MTX restores NF-κB activity to normal, in vivo.  
Analysis in cell models demonstrates that MTX induction of lincRNA-p21 is 
via DNA-PKcs dependent mechanisms and that lincRNA-p21 inhibits NF-κB 
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activity, in part, by sequestering RELA mRNA.  Collectively, our results 
demonstrate that lincRNA-p21 is a key negative regulator of NF-κB activity.  
We suggest that reduced expression of lincRNA-p21 in RA may contribute to 
the inflammation associated with this disease and that a portion of the anti-
inflammatory properties of MTX may result from induction of lincRNA-p21.   
 
Materials and Methods 
 
Reagents and Cell Culture. MTX was from Sigma-Aldrich (St. 
Louis, MO). Human TNF-α was from BD Biosciences (Bedford, MA). KU-
55933 and NU-7441 inhibitors were from Tocris Biosciences. The following 
primary antibodies were used: mouse monoclonal anti-actin (sc-8432; Santa 
Cruz Biotechnology), polyclonal rabbit-anti-JNK (sc-471; Santa Cruz 
Biotechnology), polyclonal rabbit anti-p53 (NB200-171; Novus Biologicals), 
polyclonal rabbit anti-phospho-p65 (ab10684; Abcam), monoclonal anti-
phospho-ATM (NB110-55475; Novus Biologicals), polyclonal rabbit anti-
phospho-DNA-PKcs (ab18192; Abcam). FITC-conjugated goat anti-rabbit Ig 
(554020; BD) was used as secondary antibody. The NF-κB-luciferase reporter 
(NF-κB-luc) plasmid containing five κB elements was a gift from Dean 
Ballard (Vanderbilt).  
Cell culture. Jurkat T cells were from the American Type Culture 
Collection (ATCC).  The THP-1 human monocytic cell line was a gift from 
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Jacek Hawiger (Vanderbilt). Cells were cultured in RPMI 1640 medium 
(1µg/mL folic acid) as described previously.132 Concentrations of 0.1µM or 
1.0µM MTX were used and culture periods ranged from 24 hours (activated 
primary T cells) to 48 hours (Jurkat T cells) of continuous exposure to 
MTX.132,163 Pharmacokinetic analysis indicates that ingestion of a 20-mg 
tablet of MTX produces plasma MTX concentrations of ~0.5µM after 1 hour 
and ~0.1µM after 10 hours.137,163   
Transient transfections and luciferase measurements. Jurkat T 
cells were transfected with the NF-κB-luc reporter plasmid and Silencer 
Select siRNAs (Ambion, Life Technologies) for the specified targets using the 
Cell Line Nucleofector Kit V according to the supplied protocol (Amaxa, 
Koeln, Germany). Plasmid amounts were equalized across transfections. 
THP-1 cells were transfected with Silencer Select siRNAs using 
Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s 
protocol. Luminescence was measured on a TD-20/20 Luminometer (Turner 
Designs) using Steady-Glo (E2510; Promega) according to the supplied 
protocol.  
RNA isolation, cDNA synthesis, and real-time PCR. Total RNA 
was isolated using Tri-Reagent (Molecular Research Center, Cincinnati, OH) 
for cell culture assays or by PAXgene tube (Qiagen, Germantown, MD) for 
patient studies, purified with the RNeasy MiniElute Cleanup Kit (Qiagen), 
and quantified using a Nano Drop 1000 spectrophotometer. Complementary 
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DNA (cDNA) was reverse transcribed from total RNA with the SuperScript 
III First-Strand Synthesis Kit (Life Technologies) using oligo(dT) and purified 
using the Qiagen QiaQuick PCR purification kit. Real-time qPCR (ABI-7300 
Real Time PCR System; Applied Biosystems) was performed in duplicate 
using custom or inventoried TaqMan gene expression assays in volumes of 
25µL with 50ng cDNA and TaqMan Gene Expression Master Mix.  GAPDH 
was used for normalization.   
Flow Cytometry. Cells were suspended in PBS with 10% FBS and 
0.1% azide and fixed with BD Cytofix Buffer, permeabilized using BD 
Phospho Perm/Wash Buffer (BD Biosciences), and labeled with primary 
antibodies for 24 hours at 4°C followed by incubation with FITC-labeled 
secondary antibodies for 1 hour at 4°C. Cells were analyzed using a 3-laser 
BD LSRII flow cytometer at the Vanderbilt Medical Center Flow Cytometry 
Core facility. Supplemental analysis was performed using FlowJo (Treestar, 
Ashland, OR).  
Biotin lincRNA-p21 pull down assay and bioinformatic analysis 
of lincRNA-p21 bindings sites with mRNAs. The vector expressing 
partial human lincRNA-p21 (pcDNA3-lincRNA-p21) was a gift from Dr. 
Myriam Gorospe (National Institute on Aging, NIH).  Biotinylated 
transcripts were synthesized using the MaxiScript T7 kit (+ strand) or the 
MaxiScript SP6 kit (-- strand) (Ambion) as described previously.187 Briefly, 
biotinylated transcripts were incubated with THP-1 total RNA, heated to 
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55°C, and allowed to cool for 1hr. Complexes were isolated using 
streptavidin-coupled Dynabeads (Invitrogen, Life Technologies, Grand 
Island, NY). The RNA present in the pull-down was measured using RT-
qPCR. The NCBI BLAST tool (blast.ncbi.nlm.nih.gov) was used to determine 
regions of complementarity between lincRNA-p21 and JUNB mRNA and 
RELA mRNA 187.  
Study Populations. Patient cohorts used for qRT-PCR measurements 
are summarized in Supplementary Table 5-1. RA, SLE, and SS patients met 
the American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) classification criteria. From these cohorts, western 
blotting analysis was performed on 9 control subjects (age: 48 ± 8, 7 females, 
2 males, 8 Caucasian, 1 African American) with no current chronic or acute 
infection and no family history of autoimmune disease, and 8 RA patients 
(age: 41 ± 12, 7 females, 1 male, 6 Caucasian, 2 African American). 
Demographic characteristics among control and disease cohorts did not differ 
significantly. Studies were approved by the Vanderbilt University Human 
Research Protection Program and Institutional Review Board.  Written 
informed consent was obtained at the time of blood draw.  
Western Blotting. Immunoblotting was performed as described 
previously.132 Briefly, PBMC were isolated from whole blood using BD 
Vacutainer Cell Preparation Tubes.  Whole cell lysates were resolved by SDS-
PAGE and transferred to polyvinylidene fluoride (PVDF) membranes 
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overnight at 4°C. Membranes were washed and blocked with Odyssey 
Blocking Buffer (Li-COR Biosciences, Lincoln, NE) for 1 hr at room 
temperature.  Membranes were incubated with primary antibodies overnight 
at 4°C. Membranes were washed and incubated with fluorescently labeled 
IRDye 700/800 antibodies diluted in Odyssey blocking buffer in the dark. 
Blots were washed and resuspended in TBS prior to scanning and band 
quantification using the Li-COR Odyssey Infrared Imaging System (Li-COR 
Biosciences, Lincoln, NE).   
Microarrays. Microarray analyses were performed previously (Gene 
Expression Omnibus: GSE21761 and GSE3447).147,179  
Statistical analysis. Statistically significant differences between 
tissue culture experiment groups were determined by Student’s t-test. P 
values less than 0.05 were considered significant. Unless otherwise indicated, 
results are representative of at least three independent experiments. 
Comparisons of human subject groups were calculated in two-way 
comparisons using Bonferroni’s method to correct for multiple testing, 
GraphPad Prism Software (La Jolla, CA).  
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Results 
 
TP53 and lincRNA-p21 expression in rheumatoid arthritis 
To initiate our studies, we conducted gene expression studies across 
three autoimmune diseases including rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE), and Sjogren’s syndrome (SS). We found that 
subjects with RA exhibited reduced expression of TP53 and lincRNA-p21 
relative to control subjects (CTRL) (Figure 5-1A).  These deficiencies were not 
observed in either the SLE or SS cohorts.  We concluded from these studies 
that lincRNA-p21 and TP53 levels are significantly reduced in subjects with 
RA, but this deficiency is not a common property of all inflammatory 
autoimmune diseases. Further, we measured expression of PANDA, an 
additional lncRNA induced by p53 activation. There was no significant 
difference in PANDA expression between RA and CTRL cohorts.  
The original publication describing discovery and function of lincRNA-
p21 included microarray analysis to identify genes positively or negatively 
regulated by lincRNA-p21 or TP53 based upon changes in expression levels 
following siRNA-mediated knockdown of either lincRNA-p21, TP53 or the 
combination.179  Therefore, we reasoned that genes repressed by lincRNA-p21 
or TP53 knockdown should be under-expressed in RA and genes induced by 
lincRNA-p21 or TP53 knockdown should be over-expressed in RA if lincRNA-
p21 or TP53 levels in RA contribute to RA differentially expressed gene 
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(DEG) profiles and this is exactly what we observed. In RA, approximately 
15% of the genes assayed were either over or under expressed (Figure 5-1B).  
Of these over- or under-expressed gene sets, greater than 25% of the DEGs 
correspond with the DEG profiles obtained from microarray analysis of cells 
treated with lincRNA-p21 or TP53 siRNAs. These results are consistent with 
the hypothesis that under-expression of lincRNA-p21 and TP53 played a 
large role in establishing the unique RA mononuclear cell ‘transcriptome’.  
Given these findings, we asked if transcript levels of TP53 correlated with 
transcript levels of lincRNA-p21.  In a cohort of control subjects (CTRL; 
N=20) we found no significant correlation between TP53 and lincRNA-p21 
transcript levels (Figure 5-1C). We conclude from these data that basal 
transcript levels of lincRNA-p21 were not necessarily dependent upon basal 
levels of TP53 and that p53-independent mechanisms may contribute to basal 
levels of lincRNA-p21 in mononuclear cells. Therefore, we employed pathway 
analyses to interrogate overlapping RA, lincRNA-p21, and TP53 gene sets.188 
Known NF-κB response genes, such as IL-8, were highly represented in this 
analysis.  
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Figure 5-1. Reduced expression of lincRNA-p21 in rheumatoid arthritis. A, 
TP53, lincRNA-p21, and PANDA transcript levels were measured by qRT-PCR and 
normalized to GAPDH. Whole blood samples from CTRL (n = 45), RA (n = 18), SLE (n = 
24), and SS (n = 12) subjects were collected into PaxGene tubes. B, Comparison of RA 
differentially expressed genes (DEGs) and genes significantly over-expressed (OE) or 
under-expressed (UE) following lincRNA-p21 or TP53 RNA interference. Chi-squared 
test was used to calculate P values.  C, Correlation between lincRNA-p21 and TP53 
transcripts in CTRL subjects (n = 20).  
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Figure 1. Reduced expression of lincRNA-p21 in rheumatoid arthritis. A, TP53, lincRNA-p21, and 
PANDA transcript levels were measured by qRT-PCR and normalized to GAPDH. Whole blood 
samples from healthy control (CTRL) (n = 45), rheumatoid arthritis (RA) (n = 18), systemic lupus 
erythematosus (SLE) (n = 24), and Sjogren’s syndrome (SS) (n = 12) subjects were collected into 
PaxGene tubes. B, Comparison of RA differentially expressed genes (DEGs) and genes significantly 
over-expressed (OE) or under-expressed (UE) following lincRNA-p21 or TP53 RNA interference. Chi-
squared test was used to determine P values.  C, Correlation between lincRNA-p21 and TP53 transcripts 
in CTRL subjects (n = 20). 
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MTX therapy restores lincRNA-p21 expression by DNA-PKcs 
activation.  
We next ascertained if commonly prescribed therapies for RA altered 
lincRNA-p21 expression.  MTX is often referred to as the anchor therapy for 
RA. Therefore, we asked if subjects receiving (RA+MTX) or not receiving (RA-
MTX) once-weekly doses of MTX exhibited different lincRNA-p21 transcript 
levels. We found that the RA+MTX cohort exhibited higher levels of lincRNA-
p21 transcripts than the RA-MTX cohort (Figure 5-2A). Further, no 
significant difference existed between the CTRL and RA+MTX cohort. We 
conclude from this cross-sectional study that MTX restored lincRNA-p21 
expression, in vivo, in RA.  
We next asked if MTX directly induced lincRNA-p21 expression in 
cells.  We found that treatment of either the transformed Jurkat T cell line or 
activated primary T cells with 0.1 µM MTX resulted in a 10-15 fold increase 
in lincRNA-p21 transcript levels (Figure 5-2B).   The degree of induction of 
lincRNA-p21 by MTX in both cell types was greater than the degree of 
induction of either JNK or p53 by MTX (Figure 5-2C).  Previous work 
demonstrated that MTX-mediated activation of JNK in cells induced 
increased expression of proteins contributing to cell cycle arrest and 
apoptosis.132  In certain cell types, MTX also induces increased synthesis of 
adenosine and activation of adenosine receptors.  
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Figure 5-2. Methotrexate increases expression of lincRNA-p21. A, LincRNA-p21 expression 
levels in CTRL (n = 45), RA-MTX (n = 18), and RA+MTX (n = 18) subjects were determined by 
quantitative RT-PCR.  Results are expressed as mean lincRNA-p21 relative to GAPDH transcript 
levels. B, LincRNA-p21 transcript levels in Jurkat cells or activated T cells +/- MTX. Results are 
expressed as in A.  C, Jurkat cells or activated T cells were cultured with 0.1µM MTX and 
intracellular protein measurements determined by flow cytometry. A representative flow diagram for 
JNK and p53 shows background fluorescence (left, shaded gray) and results obtained with untreated 
(middle) or MTX-treated (right) cells. Fold increase in mean fluorescence intensity (MFI) of four 
independent experiments is shown in the right graph. D, LincRNA-p21 expression in Jurkat cells 
cultured with MTX and the JNK inhibitor, BI-78D3, (left panel) or adenosine receptor antagonists, 
caffeine (CAFF) and theophylline (THEO) (right panel). Results are expressed as in A. * = p < 0.05, ** 
= p < 0.005. Values are the mean ± S.D.  NS = not significant 
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Figure 2. Methotrexate increases expression of lincRNA-p21. A, LincRNA-p2  expression levels in CTRL (n = 45), RA - MTX (n = 18), and RA + MTX (n = 18) subjects were 
determined by quantitative RT-PCR.  Results are expressed as mean lincRNA-p21 relative to GAPDH transcript levels. B, LincRNA-p21 transcript levels in Jurkat cells or 
activated T cells +/- MTX. Results are expressed as in A.  C, Jurkat cells or activated T cells were cultured with 0.1µM MTX and intracellular protein measurements 
determined by flow cytometry. A representative flow diagram for JNK and p53 shows background fluorescence (left, shaded gray) and results obtained with untreated (middle) 
or MTX-treated (right) cells. Fold increase in mean fluorescence intensity (MFI) of four independent experiments is shown in the right graph. D, LincRNA-p21 expression in 
Jurkat cells cultured with MTX and the JNK inhibitor, BI-78D3, (left panel) or ad nosine recept r antagonists, caffeine (CAFF) and theophylline (THEO) (right panel). Results 
are expressed as in A. * = p < 0.05, ** = p < 0.005. Values are the mean ± S.D.  NS = not significant
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Thus, we determined if either inhibition of JNK activation using the 
small molecular weight JNK antagonist BI-78D3 or adenosine receptor 
activation using the general adenosine receptor antagonists, caffeine and 
theophylline, was sufficient to prevent MTX-mediated elevation of lincRNA-
p21 transcript levels.  We found that inhibition of JNK activity by BI-78D3 
did not abrogate MTX-mediated induction of lincRNA-p21 (Figure 5-2D, left 
panel). We also found that adenosine receptor antagonists, caffeine and 
theophylline, did not block induction of lincRNA-p21 by MTX (Figure 5-2D, 
right panel). Taken together, these results suggest that other pathways are 
activated by MTX to induce lincRNA-p21 in these tissue culture models. 
 The original report describing the function of lincRNA-p21 
demonstrated that p53 activates human lincRNA-p21 in response to DNA 
damage.179 Deficiencies in the DNA damage response have also been reported 
in mononuclear cells from subjects with RA including reduced expression of 
p53 and two sentinels of the DNA damage response, ATM and DNA-
PKcs.84,146 Therefore, we asked if MTX-induced phosphorylation of ATM or 
DNA-PKcs.  To do so, we treated Jurkat cells with MTX and performed 
intracellular flow cytometry with specific antibodies to detect 
phosphorylated-ATM and phosphorylated-DNA-PKcs. We found that MTX 
treatment of Jurkat cells only modestly increased phosphorylation of ATM 
(Figure 5-3A).   
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Figure 5-3. Methotrexate induces lincRNA-p21 via DNA-PKcs activation. A, Jurkat cells 
were treated with the indicated concentrations of MTX for 48 hours and levels of the indicated 
phosphorylated proteins were measured by flow cytometry. Representative flow diagrams for 
phosphorylated-ATM and phosphorylated-DNA-PKcs show background fluorescence (left, shaded 
gray), untreated cells (middle) and MTX-treated (right) Jurkat cells. * = p < 0.05 versus untreated 
cells.  B, PRKDC transcript levels relative to GAPDH were measured in CTRL (n = 45), RA-MTX (n 
= 18), and RA+MTX (n = 18) subjects. C, MTX-treated Jurkat cells were co-cultured for 48 hours 
with varying concentrations of KU-55933 (KU) or NU-7441 (NU) and transcript levels of TP53 and 
lincRNA-p21 determined by qRT-PCR. * = p < 0.05 versus MTX-treated cells. See Figure 2 for other 
definitions.  
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Figure 3. Methotrexate induces lincRNA-p21 via DNA-PKcs activation. A, Jurkat cells were treated with the indicated concentrations of MTX for 48 hours and levels of the 
indicated phosphorylated proteins were measured by flow cytometry. Representative flow diagrams for phosphorylated-ATM and phosphorylated-DNA-PKcs show background 
fluorescence (left, shaded gray), untreated cells (middle) and MTX-treated (right) Jurkat cells. * = p < 0.05 versus untreated cells.  B, PRKDC transcript levels relative to 
GAPDH were measured in CTRL (n = 45), RA - MTX (n = 18), and RA + MTX (n = 18) subjects. C, MTX-treated Jurkat cells were co-cultured for 48 hours with varying 
concentrations of KU-55933 (KU) or NU-7441 (NU) and transcript levels of TP53 and lincRNA-p21 assessed by qRT-PCR. * = p < 0.05 versus MTX-treated cells. See Figure 
2 for other definitions. 
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In contrast, MTX markedly increased phosphorylation of DNA-PKcs in 
Jurkat cells.  We also compared DNA-PKcs (PRKDC) transcript levels in the 
healthy CTRL cohort to the RA+MTX and RA-MTX cohorts.  We found that 
the RA-MTX cohort exhibited reduced expression levels of PRKDC compared 
to the CTRL cohort (Figure 5-3B).  The RA+MTX cohort expressed PRKDC at 
levels equivalent to the CTRL cohort and significantly higher than the RA-
MTX cohort.  We conclude from these studies that pharmacologic doses of 
MTX increased PRKDC transcript levels in RA subjects to near control 
values.   Next, we asked using an in vitro assay if induction of TP53 and 
lincRNA-p21 by MTX in Jurkat cells could be reversed with the addition of an 
ATM or DNA-PKcs specific inhibitor. To accomplish this, we supplemented 
cultures with KU-55933, which at low concentrations (10-20nM) inhibits 
phosphorylation of ATM but at high concentrations inhibits phosphorylation 
of both ATM and DNA-PKcs (5-10µM).189-191  Supplementation of MTX-
treated cultures with the KU-55933 inhibitor at low concentrations to 
selectively inhibit ATM did not significantly alter induction of lincRNA-p21 
or TP53 by MTX (Figure 5-3C).  In contrast, treatment with MTX and high 
concentrations of KU-55933 that inhibit both ATM and DNA-PKcs 
significantly reduced induction of lincRNA-p21 and TP53 transcripts by MTX 
suggesting that induction of TP53 and lincRNA-p21 by MTX resulted from 
activation of DNA-PKcs rather than activation of ATM.  To directly test this 
hypothesis, we employed the specific inhibitor of DNA-PKcs phosphorylation, 
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NU-7441192,193, and found that treatment of Jurkat cells with NU-7441 
directly inhibited MTX-mediated induction of lincRNA-p21 and TP53 
transcripts to nearly the same level.  Taken together, these results provide 
evidence that MTX increases expression of lincRNA-p21, at least in part, 
through activation of DNA-PKcs.  
Methotrexate inhibits NF-κB activity via lincRNA-p21 
activation. 
Since deficiencies of p53 exacerbate inflammatory disease in murine 
models, rheumatoid arthritis is a disease characterized by p53 deficiency, and 
NF-κB is a critical pro-inflammatory and pro-survival transcription factor, we 
postulated that TP53 and/or lincRNA-p21 may directly interfere with NF-κB 
activity in tissue culture models. To explore this hypothesis, we measured 
activity of NF-κB using a luciferase reporter construct. We initiated our 
studies in cell lines co-transfected with the NF-κB luciferase reporter and 
Silencer Select siRNAs for TP53 and lincRNA-p21.  Cultures were untreated 
or treated with MTX for 48 hours.  TNF-α was added during the last 24 hours 
of culture to stimulate NF-κB activity.  Cultures treated MTX and TNF-α 
(transfected with a scrambled siRNA control (Neg. Ctrl)) exhibited reduced 
activation of NF-κB compared to cultures treated with TNF-α (Figure 5-4A).  
Addition of TP53 or lincRNA-p21 siRNAs significantly abrogated MTX-
mediated inhibition of NF-κB activity in Jurkat cells.   
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Figure 5-4. Methotrexate reduces NF-κB activity via DNA-PKcs activation and lincRNA-
p21 induction. A, Jurkat cells were transfected with an NF-κB luciferase reporter construct in the 
presence of TP53 (gray) and lincRNA-p21 (black) siRNAs or a scrambled siRNA control (Neg. Ctrl, 
white). Cells were treated with methotrexate (MTX) for 48 hours. TNF-α (5ng) was added to cell 
cultures after 24 hours. Results are expressed in light units.  B, As in A, Jurkat cells were 
transfected with an NF-κB luciferase reporter construct and treated with MTX in the presence or 
absence of KU-55933 (KU) or NU-7441 (NU). Results are expressed as in A.  C, Western blotting for 
phosphorylated p65 (P-p-65). Whole cell lysates were prepared in CTRL (n = 9), RA+MTX (n = 4) and 
RA-MTX subjects (n = 4). Right panel shows quantitation of band intensity relative to b-actin.  A-C, 
* = p < 0.05 
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Figure 4. Methotrexate reduces NF-κB activation via DNA-PKcs activation and lincRNA-p21 induction. A, Jurkat cells were transfected with an NF-κB luciferase reporter 
construct in the presence of TP53 (gray) and lincRNA-p21 (black) siRNAs or a scrambled siRNA control (Neg. Ctrl, white). Cells were treated with methotrexate (MTX) for 48 
hours. TNF-α (5ng) was added to cell cultures after 24 hours. Results are expressed in light units.  B, As in A, Jurkat cells were transfected with an NF-κB luciferase reporter 
construct and treated with MTX in the presence or absence of KU-55933 (KU) or NU-7441 (NU). Results are expressed as in A.  C, Western blotting for phosphorylated p65 
(p-65). Whole cell lysates were prepared in CTRL (n = 9), RA+MTX (n = 4) and RA-MTX subjects (n = 4). Right panel shows quantitation of band intensity relative to β-actin. 
A-C, * = p < 0.05
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Since we found that MTX induced lincRNA-p21 through activation of 
DNA-PKcs, we asked if inhibition of DNA-PKcs using KU-55933 (KU) or NU-
7441 (NU) also blocked inhibition of NF-κB activity by MTX. Low 
concentrations of KU-55933 that only inhibit ATM phosphorylation failed to 
prevent MTX-mediated inhibition of NF-κB activity.  In contrast, high 
concentrations of KU-55933 that inhibit phosphorylation of both ATM and 
DNA-PKcs or addition of the DNA-PKcs-specific inhibitor, NU-7441, 
effectively blocked inhibition of NF-κB activity by MTX in our cell culture 
model (Figure 5-4B).  One of the most abundant NF-κB family members is 
the p50-p65 complex.  Phosphorylation of p65 (Rel A), in response to 
exogenous stimuli, such as TNF-α, increases NF-κB transcriptional 
activity.194 Therefore, we elected to use this biomarker to measure basal 
levels of NF-κB activity in control and RA subjects by western blotting for 
phosphorylated-p65 (P-p65). Whole cell lysates were prepared from PBMC 
harvested from CTRL and RA subjects. Surprisingly, we were able to detect 
elevated basal levels of P-p65 in RA PBMC but not in CTRL (Figure 5-4C).   
Increased levels of P-p65 were not detected, however, in RA subjects 
receiving once-weekly doses of MTX.  Our conclusion from these studies is 
that chronic NF-κB activation exists in RA and is corrected by MTX therapy, 
in vivo.  
 The above results demonstrated that induction of lincRNA-p21 and/or 
TP53 transcripts by MTX contributed to MTX-mediated inhibition of 
 118 
activation of NF-κB by TNF-α.  However, they did not demonstrate if basal 
levels of lincRNA-p21 and/or TP53 transcripts contributed to basal or 
stimulus-dependent (TNF-α) NF-κB activity.  To explore this, we used siRNAs 
to specifically reduce basal levels of lincRNA-p21 or TP53 transcripts in two 
different cell lines, THP-1 cells, which is of the monocyte lineage, and Jurkat 
cells.  In THP-1 cells, siRNA-mediated specific reduction of lincRNA-p21 or 
TP53 transcripts resulted in increased basal and TNF-α induced NF-κB 
activity (Figure 5-5A).  In Jurkat cells, siRNA-mediated reduction of 
lincRNA-p21 levels, but not TP53 levels, resulted in increased basal and 
TNF-α induced NF-κB activity.  This difference is due, in part, to decreased 
efficiency of siRNA-mediated knockdown of TP53 transcripts in Jurkat cells.  
These studies demonstrated that lincRNA-p21 is a direct negative regulator 
of both basal and stimulus-induced NF-κB activity. 
 Previous studies have demonstrated that lincRNA-p21 inhibits 
expression of genes encoding pro-survival proteins to induce apoptosis in 
response to DNA damage.178,179,187 Further, lincRNA-p21 binds to mRNAs, 
such as JUNB and CTNNB1 and inhibits their translation.179,187 Thus, we 
reasoned that lincRNA-p21 may inhibit NF-κB activity by altering transcript 
levels of genes that encode proteins critically involved in NF-κB signaling 
pathways or that lincRNA-p21 may actually bind to these mRNAs and thus 
lower rates of translation.  We performed two studies to help discriminate 
between these two possibilities.   
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Figure 5-5. Association of RELA and lincRNA-p21 transcripts. A, THP-1 
(left) or Jurkat (right) cells were transfected with an NF-κB luciferase reporter 
construct in the presence of specific siRNAs targeting lincRNA-p21 (black), 
TP53 (gray), or a scrambled siRNA control (Neg. Ctrl, white). Luminescence 
was quantified 48 hours post-transfection.  TNF-α (5ng) was administered to 
cultures at 24 hours post-transfection. * = p < 0.05 B, THP-1 cells were 
transfected with a lincRNA-p21 siRNA and qRT-PCR measurements of the 
indicated transcripts measured 48 hours post-transfection. * = p < 0.05 versus 
cells transfected with a negative control siRNA. C, Sites of high 
complementarity between RELA and JUNB mRNA and lincRNA-p21 and D, 
relative enrichment as determined by qRT-PCR of RELA and JUNB mRNAs 
purified with a lincRNA-p21 biotinylated probe. * = p <0.05 versus 18S and 
NFKB1 transcript levels.  
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Figure 5. Association of RELA and lincRNA-p21 transcripts. A, THP-1 (left) or Jurkat (right) cells 
were transfected with an NF-κB luciferase reporter construct in the presence of specific siRNAs 
targeting lincRNA-p21 (black), TP53 (gray), or a scrambled siRNA control (Neg. Ctrl, white). 
Luminescence was quantified 48 hours post-transfection.  TNF-α (5ng) was administered to cultures 
at 24 hours post-transfection. * = p < 0.05 B, THP-1 cells were transfected with a lincRNA-p21 siRNA 
and qRT-PCR measurements of the indicated transcripts measured 48 hours post-tra sfection. * = p < 
0.05 versus cells transfected with a negativ  control siRNA. C, Sites of high complementarity b tween 
RELA and JUNB mRNA and lincRNA-p21 and D, relative enrichment as determined by qRT-PCR of 
RELA and JUNB mRNAs purified with a lincRNA-p21 biotinylated probe. * = p <0.05 versus 18S and 
NFKB1 transcript levels. 
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We employed lincRNA-p21 specific siRNAs to knockdown levels of lincRNA-
p21.  We found that loss of lincRNA-p21 did not produce a corresponding gain 
in transcript levels of NFKB1 or RELA suggesting that lincRNA-p21 did not 
interfere with cellular NF-κB activity by lowering NFKB1 or RELA transcript 
levels (Figure 5-5B). To test the alternate hypothesis, that lincRNA-p21 may 
associate with RELA and/or NFKB1 mRNAs and inhibit their translation, we 
used a bioinformatics approach to identify regions of complementarity 
between lincRNA-p21 and JUNB (as control) and RELA, the gene whose 
protein product encodes for p65.  We identified 8 regions of high 
complementarity between lincRNA-p21 and JUNB, mirroring previously 
published findings187 and further identified 6 sites of high complementarity 
between lincRNA-p21 and RELA (Figure 5-5C).  The interactions between 
endogenous levels of lincRNA-p21 and JUNB and RELA were quantified 
using an antisense, biotinylated lincRNA-p21 RNA as described previously.187 
Similar to the known ability of lincRNA-p21 to associate with JUNB, we 
found that lincRNA-p21 had a significantly higher interaction with RELA 
transcripts than NFKB1 or 18S transcripts (Figure 5-5D).  Our work suggests 
that one way lincRNA-p21 may function is through binding to mRNAs that 
encode proteins critical for NF-κB transcriptional activity.  
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Discussion 
 
Increased expression of P-p65, a necessary component of NF-κB 
transcriptional activity, and decreased expression of lincRNA-p21 are present 
in RA subjects not receiving MTX therapy. Treatment with MTX corrects 
both defects, in vivo.  Our results support a model whereby MTX induces 
lincRNA-p21 expression via a DNA-PKcs dependent pathway and that 
lincRNA-p21 directly inhibits both basal and TNF-α stimulated NF-κB 
activity.  Inhibition of NF-κB activity results, at least in part, by the ability of 
lincRNA-p21 to sequester RELA mRNA.  Thus, reduced expression of 
lincRNA-p21 and p53 contributes to increased activity of the pro-
inflammatory and pro-survival transcription factor NF-κB.  We propose that 
reduced expression of these pro-apoptotic and anti-inflammatory RNAs and 
proteins in RA contributes to the chronic inflammation observed in RA.  
MTX is generally considered an anchor therapy for treatment of RA.  
Its anti-inflammatory effects are incompletely understood.   Two known 
pathways activated by MTX are stimulation of adenosine release and 
activation of adenosine receptors, which has anti-inflammatory properties, 
and activation of JNK enzymes to induce pro-apoptotic proteins leading to 
heightened sensitivity to apoptosis.132  Activation of DNA-PKcs by MTX 
appears to be independent of these two pathways.  Phosphorylation 
(activation) of DNA-PKcs and ATM in response to DNA damage is reasonably 
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well understood.  However, phosphorylation of ATM is not observed in 
response to MTX suggesting that induction of DNA damage by MTX is not 
responsible for phosphorylation of DNA-PKcs in our culture systems.  DNA-
PKcs activation also plays a critical role in cellular responses to replicative 
stress.73  Thus, it is possible that MTX may induce replicative stress via 
inhibition of DHFR or other mechanisms to activate DNA-PKcs independent 
of ATM.  Using selective inhibitors of DNA-PKcs and ATM, we clearly show 
that induction of lincRNA-p21 and TP53 by MTX is dependent upon DNA-
PKcs and not ATM and that MTX mediated inhibition of NF-κB activity in 
our culture systems requires DNA-PKcs.  Our interpretation is that MTX 
induces phosphorylation of DNA-PKcs leading to induction of TP53 and 
lincRNA-p21.  In turn, elevated activity of p53 and lincRNA-p21 inhibits 
basal and stimulus-induced NF-κB activity.   
LincRNA-p21 is upstream of CDKN1A (Supplemental Figure 5-1) in 
the genome and belongs to a class of lncRNAs induced by p53 in response to 
DNA damage.182 In blood cells, baseline levels of TP53 and lincRNA-p21 are 
not well correlated.  In the absence of DNA damage, genes responsive to 
TP53 ‘knockdown’ or lincRNA-p21 ‘knockdown’ are not identical (16).   Both 
classes of genes are highly over-represented in the class of genes found to be 
over or under-expressed in RA.  Thus, we believe our results and results of 
others support the notion that TP53 and lincRNA-p21 transcript levels are 
regulated by both common pathways in response to, for example, extensive 
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DNA damage as well as by independent pathways.  Further, gene expression 
programs regulated by p53 and lincRNA-p21 are not identical.  Further 
experimentation will be required to identify underlying mechanisms leading 
to reduced expression of TP53 and lincRNA-p21 in RA and the full spectrum 
of consequences in RA produced by reduced expression of TP53 and lincRNA-
p21.   
Two mechanisms are known by which lincRNA-p21 affects cellular 
function. First, in the nucleus, lincRNA-p21 mediates transcriptional 
repression of target genes through association with heterogeneous nuclear 
ribonucleoprotein-K (hnRNP-K).179  Second, in the cytoplasm, lincRNA-p21 
associates with target mRNAs, such as JUNB and CTNNB1, to prevent their 
translation.187  In our analysis, reduced lincRNA-p21 levels do not alter 
transcript levels of NF-κB genes, NFKB1 or RELA. Rather, lincRNA-p21 
binds RELA mRNA thus possibly interfering with mRNA translation, a 
result consistent with the second mechanism.  However, we cannot rule out 
the possibility that lincRNA-p21 may inhibit transcription of other mRNAs 
that encode proteins required for NF-κB activation or represses translation of 
these same mRNAs.  Nevertheless, our results indicate that lincRNA-p21 
possesses regions of mRNA sequence homology with RELA mRNA and 
associates with RELA mRNA under physiologic conditions.   
Existence of defects in the transcriptional response leading to cell cycle 
arrest and apoptosis in RA are well established.  These same defects are 
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corrected, at least in part, by one of the major therapies for RA, MTX.163  
What has been unclear is how these defects may contribute to underlying 
chronic inflammation that is a hallmark of RA.  We propose that one 
mechanism is that p53 and lincRNA-p21 are negative regulators of NF-κB 
activity.  As such, reduced levels of p53 and lincRNA-p21 produce enhanced 
basal and stimulus-dependent NF-κB activity and restoration of levels of p53 
and lincRNA-p21 by MTX also lowers NF-κB activity, a major driver of the 
pro-inflammatory state of RA.  Future studies will be required to determine if 
understanding interplay between these two pathways can be exploited for 
therapeutic benefit in RA.   
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CHAPTER VI 
 
GENERAL DISCUSSION AND CONCLUSION 
 
While initially developed as a chemotherapeutic, methotrexate (MTX) 
has been the mainstay for RA treatment for nearly four decades. Once-weekly 
administration of 7.5 to 25 milligrams yields optimal clinical outcomes, 
compared to the 5000 mg/week dosage used in the treatment of 
malignancy.1,3 RA patients treated with MTX experience reduced pain, and 
improved joint score and function typically within three months of treatment. 
The tight control and suppression of inflammation in early stages of disease 
has been advocated as the basis of documented disease modifying effects. Yet, 
the mechanisms accounting for the anti-inflammatory effects of MTX remain 
incompletely understood. Questions also remain as to the specific targets 
necessary to develop new therapeutics beyond MTX for the treatment of RA.  
The initial studies of rheumatoid arthritis in our laboratory examined 
differential expression of genes in healthy control subjects and patients 
diagnosed with autoimmune disease.  The goal of these experiments was to 
identify a subset of genes that could distinguish between healthy individuals 
and patients with autoimmune disease.  We found that patients with 
rheumatoid arthritis significantly underexpressed a panel of genes that are 
typically considered prototypical cancer genes in peripheral blood 
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mononuclear cells. Specifically, these studies established that defects in 
expression of CHEK2, TP53, CDKN1A, and CDKN1B conferred an inability 
for RA lymphocytes to undergo apoptosis in response to gamma irradiation.18 
The major obstacle moving forward was how to link these observations to RA 
disease pathogenesis. Further, we found that a subset of RA subjects 
exhibited increased expression of JUN target mRNA. A unique characteristic 
of these RA subjects was that they were all receiving low-dose methotrexate 
therapy. From this observation, we were then able to reproduce in tissue 
culture MTX-dependent JUN activation in T cells treated with sub-
micromolar doses of MTX. These experimental findings have been the area of 
intensive study during my time in the laboratory and have led to the 
elucidation of a novel series of biochemical pathways for low-dose MTX 
therapy.  
In the first chapter we found that Jun-N-terminal kinase (JNK) a MAP 
kinase, is activated in response to methotrexate therapy. Through JNK, 
methotrexate increases the sensitivity of T cells to apoptosis through 
production of reactive oxygen species and alteration of the transcriptional 
profile in favor of genes whose protein products promote apoptosis including 
activation of JUN mRNA. This process is mediated by MTX inhibition of 
dihydrofolate reductase (DHFR), which blocks the reduction of 
dihydrobiopterin (BH2) to tetrahydrobiopterin (BH4).  Since our in vivo 
studies of RA patients on low-dose MTX therapy revealed elevated levels of 
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the prototypical JNK-target gene, JUN, in response to MTX, our data support 
the notion that the JNK pathway is activated by MTX, in vivo, and may 
contribute to the efficacy of MTX in inflammatory disease. Specifically, we 
now hypothesize that the therapeutic efficacy of MTX may arise at least in 
part from its ability to deplete BH4 causing both a shift in cytokine profiles 
from a pro-inflammatory profile to an anti-inflammatory profile and 
initiation of the clearance of self-reactive inflammatory lymphocytes by 
apoptosis.  
In chapter two, we further probed the mechanism by which MTX 
increases sensitivity of cells to apoptosis and asked if methotrexate restores 
the cell cycle checkpoint deficiencies we have observed previously. Since MTX 
increased levels of JNK in tissue culture, we asked if levels of JNK were 
decreased in subjects with RA not receiving MTX. We found highly 
significant deficiencies of MAPK9 (JNK2) expression in rheumatoid arthritis.  
Analysis of other MAPK family members including most known ERK and p38 
isoforms did not reveal any significant difference in healthy controls versus 
RA cohorts receiving or not receiving methotrexate. Following our gene 
expression studies, we analyzed protein expression in RA lymphocytes and 
found that these subjects exhibit reduced JNK expression. Analysis of 
additional autoimmune diseases also indicated that this MAPK9 deficiency 
observed in RA was not unique, but also extends to multiple sclerosis (MS).  
It is interesting to note that RA and MS exhibit similar molecular defects in 
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PBMC specifically through reduced checkpoint kinase 2 (CHEK2), p53 and 
ataxia telangiectasia (AT) mutated (ATM) expression.83 The contribution of 
JNK to these defects remains to be explored. We found that MTX increased 
levels of both p53 and the downstream target p21 in MTX-treated cells via 
JNK, which was further confirmed in vivo analyzing transcript levels of TP53 
and CDKN1A mRNAs in subjects receiving and not receiving MTX therapy. 
These MTX-mediated effects are critically dependent upon MTX depletion of 
BH4, generation of ROS, and activation of JNK.  Through loss of ATM, RA T 
cells accumulate a significant amount of DNA damage.84 One hypothesis is 
that DNA damage repair deficiencies coupled with depressed levels of p53 
and JNK blunt the central pathways of apoptosis resulting in cell survival 
but loss of genomic integrity. Cell survival comes at a cost and the cost is 
persistent DNA damage, which may induce NF-κB or alternative pro-
inflammatory, pro-survival pathways leading to the ‘sterile inflammation’ 
observed in RA pathogenesis.  
Our next series of experiments analyzed the influence of methotrexate 
upon transcriptional levels of NF-κB, a central regulator of the inflammatory 
response, in two cells types: T cells and primary fibroblast-like synoviocytes 
(FLS) from RA subjects. We also examined the PBMC of RA patients 
receiving and not receiving MTX and found that increased levels of 
phosphorylated p65 were present in the cohort of RA subjects not receiving 
MTX, but this signal was absent in RA patients currently on methotrexate. 
 129 
In tissue culture experiments, administration of MTX decreased TNF-α-
dependent activation of NF-κB in both synoviocytes and T cells, but the 
observed mechanism was divergent across the two cell types. In T cells, the 
BH4 pathway we have described possessed anti-inflammatory properties via 
induction of JNK and p53 as depletion of both of these proteins with 
dominant negative mutants abrogated the inhibitory effects of MTX on T cells 
in vitro. In contrast, reduced activity of NF-κB in FLS was reversed not by 
BH4 or JNK. Rather, adenosine receptor antagonists caffeine and/or 
theophylline almost completely reversed the effects of MTX in these cells, 
which follows closely with much of the published work concerning the 
mechanism of action of MTX over the past two decades.13,23,38-40,106,108,195 Thus, 
we conclude that MTX modulates NF-κB through distinct mechanisms in 
these cell types.  
We further explored the connection between NF-κB and p53, as these 
are two central regulators of the adaptive immune response. NF-κB 
modulates the response to exogenous stimuli, whereas p53 modulates the 
intrinsic stress responses through initiation of “cell cycle arrest, apoptosis, or 
senescence, eliminating clones of cells with DNA damage and its results 
mutations”.173 Examination of the PBMC and synovium of RA subjects 
demonstrates that NF-κB is significantly overexpressed. Also present are 
reduced levels of p53. p53 drives induction of genes that both prevent DNA 
damage and repair damaged DNA. Together with NF-κB, these master 
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regulators of internal and external stimuli must achieve a careful balance. 
Each transcription factor responds to a different form of cellular stress, 
adopting two very different strategies that have evolved into mutually 
exclusive processes under normal physiologic conditions.173 A downstream 
target of p53 activity is the activation of the long, non-coding RNA, lincRNA-
p21. Similar to our p53 findings, we observed decreased levels of lincRNA-
p21. This deficiency of lincRNA-p21 expression was corrected in subjects 
receiving MTX. Introduction of specific siRNA duplexes targeting lincRNA-
p21 prevented MTX-mediated reduction of NF-κB in T cells. To ascertain 
mechanism, we examined if induction of lincRNA-p21 by MTX could be 
abrogated with supplementation of either BH4 or JNK inhibitors. We find 
that activation of the BH4 pathway does not modulate lincRNA-p21 
activation. Rather, phosphorylation of DNA-PKcs was necessary to induce 
expression of lincRNA-p21. Surprisingly, activation of p53 by two distinct 
pathways results in inhibition of NF-κB activity.  We conclude from these 
observations that multiple pathways exist in T cells to restore the p53 
response in RA subjects receiving low doses of MTX. A graphic summary of 
the pathways we have discovered as a result of these studies is summarized 
in Figure (6-1). 
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 One hundred years ago, the only drug in the physician 
armamentarium to manage RA was aspirin.196 Soon after, gold salts were 
commonly prescribed from approximately 1930-1980. Penicillamine, anti-
malarial drugs, and sulfasalazine were subsequently introduced from in the 
1970s and 1980s.10 However, despite introduction of these pharmacologics, 
the disease course of most RA patients progressed and was not adequately 
controlled. It wasn’t until the introduction of disease-modifying anti-
rheumatic drugs, such as methotrexate, that physicians saw significant 
improvement in long-term outcomes, especially when methotrexate was 
combined with other therapies. When we initiated our studies to examine the 
anti-inflammatory properties of methotrexate, we thought that there would 
be a single biomarker we could target to achieve the same outcome with less 
toxicity, as subjects taking methotrexate have reported hair loss, nausea, and 
fatigue. However, as we examine the molecular basis for this drug in RA, we 
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Figure 6-1. Summary of known and novel mechanisms of MTX action. 
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find that not only does it stimulate the adenosine pathway, which results in 
reduced NF-κB activation in FLS, but it also activates the BH4 pathway and 
induces lincRNA-p21 in T cells.  Both of these pathways lower NF-κB 
transcriptional activity and function in vivo in RA.  
Targeted therapies that have been approved over the past decade have 
resulted in many first-in-class drugs.  However, the majority of these first in 
class drugs were the result of phenotypic assay screening, and not through 
targeted approaches.197 Interestingly, most targeted approaches result in 
follow-on drugs that are prescribed in combination with other ‘anchor’ 
therapies in human disease. An interesting area of future investigation would 
be to design small molecules that selectively target BH2 reduction to BH4 and 
alternatively induce lincRNA-p21 expression. Given the diverse effects we see 
both in vitro and in vivo in RA patients receiving MTX, it would be difficult to 
point to a single therapy that could supplant the multi-faceted pathway MTX 
employs in the management of RA.  While these new therapeutics could be of 
utility, an important future direction of this work is setting the stage for a 
better understanding the origins of the cellular defects we have observed. We 
would argue that treatment of the most proximal events in disease 
pathogenesis lead to more effective therapeutic strategies and improved 
clinical outcomes. Most newly developed therapies attempt to disrupt the 
downstream NF-κB activation-pro-inflammatory cytokine loop, such as 
Enbrel (etanercept) through blockade of TNF-α. We argue that interfering 
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with the upstream pathways of deficiency cell cycle arrest and DNA repair 
will produce improved therapeutic outcomes for subjects with RA. To this 
end, we have considered prevailing theories of immunity and autoimmunity. 
The general view is that initiation of adaptive immune responses to 
pathogens is divided into two parts, the recognition of ‘danger’ via the innate 
immune system and the recognition of foreign antigen by the adaptive 
immune system.198,199 It is widely accepted that a breach in tolerance in the 
adaptive immune response leads to recognition of self-antigen contributing to 
autoimmunity. In this model, the source of ‘danger’ to initiate the immune 
response to self has never been completely identified.198 We would propose a 
new model whereby the source of ‘danger’ is actually internal or intracellular 
and not external, which we will explore in a new series of experiments. This 
model is summarized in Figure 6-2.  
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In our model, DNA damage accumulates every day in individuals as a 
result of environmental exposures, UV or ionizing radiation, oxidative stress, 
chemical exposures, cell replication, inflammatory stress in response to 
infection, normal metabolic activities produce oxidants, or 
smoking.69,71,82,153,200-203 Smoking is well established as a significant 
environmental risk factor for RA. Normally, activation of cell cycle 
checkpoints and the DNA repair machinery repair DNA damage. However, in 
RA, via intrinsic mechanisms regulated by the presence of HLA-DRB1*04 
alleles or other pathways, these repair mechanisms, ATR, DNA-PKcs, and 
ATM, and cell cycle checkpoints, JNK2, p53, p21, p27, CHEK2, RANGAP1 
are defective, resulting in failure to repair DNA and loss of genomic 
integrity.85,175,204-206 Failure to repair DNA and/or cell cycle checkpoint defects 
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Figure 6-2. Schematic illustrating proposed inter-
relationships between environmental exposures and genetic 
liabilities to produce failure of DNA damage repair, chronic 
NF-κB activation and inflammation leading to RA.  
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results in chronic NF-κB activation and induction of pro-inflammatory 
cytokines, producing a continuous cycle of events causing chronic 
inflammation, which underlies the pathogenesis of RA. If the origins of these 
defects could be corrected, this may even result in a cure.  Future studies are 
planned to examine the contribution of these defects to the etiopathogenesis 
of RA.  
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SUPPLEMENTAL DATA  
 
APPENDIX A 
Supplemental Table 2-1. Regulation of genes encoding proteins 
involved in apoptosis by MTX is JNK-mediated. 
 
Gene MTX,-8M, 48hr 
 
MTX,-7M, 48hr 
 
 MTX, -6M, 48 hr 
Symbol 
MEA
N   STDEV  TTEST MEAN STDEV  TTEST MEAN STDEV TTEST 
18S 0.9 0.3 NS* 1.5 1.4 NS 1.0 0.7 NS 
ACTB 0.5 0.1 NS 1.3 0.7 NS 1.6 0.6 NS 
APAF1 0.9 0.3 NS 1.4 0.6 NS 1.8 0.5 NS 
BAD 0.7 0.5 NS 1.9 0.3 0.02 2.9 1.7 NS 
BAK1 0.9 0.0 NS 2.0 0.4 0.04 2.8 1.3 NS 
BAX 0.8 0.5 NS 2.2 1.0 NS 4.0 2.8 NS 
BBC3 0.5 0.2 NS 5.9 1.8 0.04 6.0 1.9 0.04 
BCAP31 1.6 0.1 NS 1.6 0.5 NS 1.5 0.4 NS 
BCL10 1.2 0.5 NS 2.5 1.4 NS 2.7 1.5 NS 
BCL2 1.5 0.7 NS 4.6 1.9 NS 4.2 1.4 NS 
BCL2A1 2.1 1.3 NS 2.5 1.3 NS 2.9 1.1 NS 
BCL2L1 0.4 0.1 NS 1.2 0.3 NS 1.5 0.8 NS 
BCL2L11 1.0 0.3 NS 2.9 1.3 NS 4.9 4.1 NS 
BCL2L13 0.3 0.0 NS 1.4 1.4 NS 2.0 1.4 NS 
BCL2L2 ND** ND ND ND ND ND ND ND ND 
BCL3 1.2 0.3 NS 10.5 1.9 0.01 14.4 3.9 0.03 
BID 2.2 0.4 NS 1.1 0.1 NS 1.2 0.3 NS 
BIK 1.4 0.2 NS 3.5 1.0 0.04 2.8 2.1 NS 
BIRC1 1.4 0.1 NS 2.1 1.5 NS 1.1 1.8 NS 
BIRC2 1.1 0.1 NS 1.1 0.7 NS 1.3 1.0 NS 
BIRC3 1.6 0.0 NS 1.9 1.2 NS 2.2 1.2 NS 
BIRC4 0.8 0.4 NS 2.5 1.5 NS 6.5 7.5 NS 
BIRC5 1.4 0.4 NS 1.9 0.4 0.04 2.1 0.2 0.00 
BIRC6 0.5 0.2 NS 1.3 1.0 NS 1.7 1.0 NS 
BIRC8 1.6 1.0 NS 3.8 0.4 0.00 10.5 3.6 0.04 
BNIP3 1.3 0.3 NS 0.5 0.3 NS 0.5 0.2 0.03 
BNIP3L 1.4 0.4 NS 1.0 0.2 NS 1.0 0.1 NS 
BOK 0.8 0.2 NS 4.4 1.4 0.01 5.6 1.2 0.01 
CARD4 0.2 0.0 NS 1.2 0.9 NS 2.3 1.7 NS 
CARD9 1.4 0.4 NS 8.9 2.9 0.04 9.6 2.2 0.02 
CASP1 2.2 0.1 NS 6.2 1.4 0.01 7.2 2.3 0.01 
CASP10 0.5 0.0 NS 3.2 1.6 NS 3.7 2.1 NS 
CASP2 0.6 0.0 NS 2.0 0.7 NS 2.9 1.2 NS 
CASP3 1.0 0.1 NS 2.2 1.2 NS 2.3 0.8 NS 
CASP4 1.6 0.2 NS 1.8 0.8 NS 1.9 0.7 NS 
CASP6 1.8 0.1 NS 2.8 2.2 NS 3.2 1.9 NS 
CASP7 1.7 0.7 NS 1.8 1.2 NS 2.6 1.4 NS 
CASP8 0.6 0.4 NS 1.9 0.8 NS 2.9 1.5 NS 
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CASP8AP2 1.4 0.0 NS 2.2 0.9 NS 2.9 2.2 NS 
CFLAR 1.0 0.3 NS 1.8 0.6 NS 1.9 0.9 NS 
CHUK 1.8 0.7 NS 1.8 0.9 NS 1.7 0.8 NS 
CRADD 1.6 0.2 NS 1.1 0.4 NS 1.2 0.6 NS 
DAPK1 0.6 0.4 NS 3.2 1.6 NS 4.5 3.3 NS 
DEDD 1.0 0.2 NS 1.3 0.5 NS 1.4 0.5 NS 
DEDD2 0.8 0.1 NS 1.4 0.1 0.01 2.2 0.5 0.04 
DIABLO 1.3 0.3 NS 1.4 0.3 NS 1.6 0.5 NS 
        
Gene 
MTX 
[-8M 
48hr] 
  
MTX  
[-7M 
48hr] 
  
 MTX  
[-6M 48 
hr] 
  
Symbol MEAN   STDEV  TTEST MEAN STDEV  TTEST MEAN 
STDE
V TTEST 
ESRRBL1 2.3 0.3 NS 2.5 1.0 NS 2.6 1.6 NS 
FADD 1.0 0.0 NS 1.5 0.7 NS 1.7 0.8 NS 
FAS 1.7 0.8 NS 2.8 0.8 NS 3.7 0.4 0.01 
GAPDH 1.0 0.0 NS 1.0 0.0 NS 1.0 0.0 NS 
HIP1 0.7 0.3 NS 2.3 1.7 NS 2.0 0.9 NS 
HRK 1.1 0.4 NS 6.9 2.1 0.04 10.3 2.7 0.03 
HTRA2 1.4 0.5 NS 1.5 0.6 NS 1.8 1.0 NS 
IKBKB 0.6 0.2 NS 0.8 0.3 NS 1.2 0.5 NS 
IKBKE 1.4 0.2 NS 3.4 1.9 NS 3.5 2.3 NS 
IKBKG 0.7 0.1 NS 1.9 0.4 0.05 2.5 0.6 0.03 
LRDD 0.1 0.0 NS 2.0 1.2 NS 3.0 1.2 NS 
LTA 0.9 0.3 NS 2.8 1.2 NS 2.7 1.5 NS 
LTB 1.5 1.5 NS 6.1 1.4 NS 13.8 4.9 0.02 
MCL1 1.0 0.4 NS 2.8 2.3 NS 4.1 2.9 NS 
NALP1 2.5 3.3 NS 1.7 0.9 NS 2.4 1.6 NS 
NFKB1 2.3 0.7 NS 2.8 1.3 NS 2.6 1.7 NS 
NFKB2 0.3 0.1 NS 1.9 0.3 0.01 2.6 0.3 0.00 
NFKBIA 1.7 0.0 NS 2.9 1.1 NS 2.4 1.4 NS 
NFKBIB 1.2 0.2 NS 2.4 1.1 NS 2.8 1.8 NS 
NFKBIE 0.8 0.1 NS 2.1 0.6 NS 2.8 1.4 NS 
PEA15 0.5 0.0 NS 2.5 1.0 NS 2.9 0.9 0.06 
PMAIP1 1.6 0.7 NS 2.1 1.4 NS 2.3 1.5 NS 
REL 0.9 0.1 NS 2.3 1.0 NS 3.4 1.7 NS 
RELA 0.5 0.3 NS 1.3 0.2 NS 1.5 0.3 NS 
RELB 1.2 0.3 NS 2.6 1.2 NS 8.3 3.0 NS 
RIPK1 0.8 0.2 NS 2.4 1.3 NS 3.2 1.2 NS 
TA-NFKBH 0.9 0.3 NS 2.7 1.8 NS 3.1 1.8 NS 
TBK1 2.0 0.7 NS 2.1 0.8 NS 2.2 1.3 NS 
TNF 1.5 0.7 NS 7.5 3.5 NS 7.4 2.4 0.04 
TNFRSF10A 0.9 0.2 NS 9.0 2.7 0.03 8.4 2.1 0.02 
TNFRSF10B 0.5 0.3 NS 1.8 0.4 0.05 2.3 0.5 0.03 
TNFRSF1A 0.4 0.2 NS 1.3 0.4 NS 1.3 0.5 NS 
TNFRSF1B 1.2 0.4 NS 4.9 0.2 0.00 13.7 3.9 0.03 
TNFRSF21 0.5 0.0 NS 1.5 0.5 NS 1.6 0.7 NS 
TNFRSF25 2.0 0.7 NS 7.2 1.6 0.02 7.4 2.2 0.04 
TNFSF10 1.7 0.3 NS 10.2 3.9 0.05 10.6 2.3 0.02 
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TRADD 1.7 0.4 NS 2.3 0.7 NS 2.6 1.4 NS 
          Legend:  Experimental details as in Fig. 2-2.  Mean and S.D. determined from fold difference between treated 
and untreated cultures.   
    *NS: not significant 
        **ND: transcript not detected,  
      T test: page 1-2 determines significance between untreated and MTX-treated cultures 
T test: page 3-4 determines significance between MTX treated cultures and MTX + 
JNK-inhibitor treated cultures 
 
      Gene  MTX,-6M, 48 hr  MTX,-6M+JNK-I,-5M, 48 hr 
Symbol MEAN STDEV 
 
MEAN STDEV 
 
TTEST 
18S 1.4 0.5 
 
0.9 0.4 
 
NS 
ACTB 1.3 0.5 
 
1.6 1.2 
 
NS 
APAF1 1.6 0.7 
 
1.9 0.8 
 
NS 
BAD 2.7 1.5 
 
1.2 0.5 
 
NS 
BAK1 3.1 0.8 
 
1.1 0.6 
 
NS 
BAX 3.4 2.4 
 
2.2 1.8 
 
NS 
BBC3 6.5 1.1 
 
2.6 1.4 
 
NS 
BCAP31 1.4 0.5 
 
0.9 0.6 
 
NS 
BCL10 2.2 1.2 
 
1.2 0.8 
 
NS 
BCL2 4.5 1.3 
 
3.2 1.1 
 
NS 
BCL2A1 2.8 1.6 
 
1.3 1.1 
 
NS 
BCL2L1 1.4 0.5 
 
1.6 0.6 
 
NS 
BCL2L11 4.4 4.0 
 
1.6 1.4 
 
NS 
BCL2L13 2.6 1.3 
 
1.8 1.2 
 
NS 
BCL2L2 ND ND 
 
ND ND 
 
ND 
BCL3 15.8 3.3 
 
3.1 1.1 
 
0.01 
BID 1.3 0.6 
 
0.7 0.4 
 
NS 
BIK 2.2 1.1 
 
1.7 0.8 
 
NS 
BIRC1 1.8 0.8 
 
2.8 1.2 
 
NS 
BIRC2 1.4 0.9 
 
1.1 0.6 
 
NS 
BIRC3 2.3 1.5 
 
2.5 1.2 
 
NS 
BIRC4 4.5 3.5 
 
3.1 3.1 
 
NS 
BIRC5 2.8 0.2 
 
2.0 1.4 
 
NS 
BIRC6 1.8 1.5 
 
1.7 1.1 
 
NS 
BIRC8 11.4 3.8 
 
1.6 1.4 
 
0.02 
BNIP3 0.8 0.6 
 
0.7 0.5 
 
NS 
BNIP3L 1.4 0.8 
 
1.5 0.7 
 
NS 
BOK 6.3 0.8 
 
2.9 0.6 
 
0.02 
CARD4 2.2 1.2 
 
2.9 0.9 
 
NS 
CARD9 10.3 2.1 
 
0.9 0.5 
 
0.01 
CASP1 8.4 2.5 
 
1.0 0.9 
 
0.00 
CASP10 4.7 2.4 
 
2.1 1.9 
 
NS 
CASP2 2.6 2.0 
 
3.8 1.7 
 
NS 
CASP3 2.7 1.0 
 
1.4 0.8 
 
NS 
CASP4 1.7 0.9 
 
1.3 0.9 
 
NS 
CASP6 3.4 1.6 
 
1.9 1.2 
 
NS 
CASP7 2.2 1.3 
 
1.2 1.0 
 
NS 
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CASP8 2.6 1.2 
 
2.1 0.9 
 
NS 
CASP8AP2 2.5 1.2 
 
0.8 0.6 
 
NS 
CFLAR 1.8 0.7 
 
1.2 0.9 
 
NS 
CHUK 1.3 1.0 
 
1.5 1.1 
 
NS 
CRADD 1.4 0.7 
 
1.4 0.6 
 
NS 
DAPK1 3.5 2.1 
 
3.9 1.5 
 
NS 
DEDD 1.2 0.3 
 
1.0 0.4 
 
NS 
DEDD2 2.3 0.8 
 
1.7 1.1 
 
NS 
DIABLO 1.8 0.8 
 
1.5 0.8 
 
NS 
	  
Gene  MTX  
  
 MTX  
[+JNK-I 
   Symbol MEAN STDEV 
 
MEAN STDEV 
 
TTEST 
ESRRBL1 2.7 1.3 
 
2.3 1.3 
 
NS 
FADD 1.9 1.2 
 
1.9 1.4 
 
NS 
FAS 4.3 0.2 
 
2.6 0.4 
 
NS 
GAPDH 1.0 0.0 
 
1.0 0.0 
 
NS 
HIP1 2.2 1.2 
 
1.4 0.9 
 
NS 
HRK 14.1 2.2 
 
1.5 1.1 
 
0.00 
HTRA2 1.4 1.4 
 
1.6 1.1 
 
NS 
IKBKB 1.4 0.7 
 
1.8 9.0 
 
NS 
IKBKE 3.1 2.0 
 
1.0 1.4 
 
NS 
IKBKG 2.9 1.6 
 
1.5 1.2 
 
NS 
LRDD 3.7 1.6 
 
4.4 1.9 
 
NS 
LTA 2.3 0.5 
 
1.2 1.1 
 
NS 
LTB 10.9 3.6 
 
2.4 1.1 
 
0.00 
MCL1 4.8 3.0 
 
2.5 2.8 
 
NS 
NALP1 2.6 1.5 
 
2.4 1.9 
 
NS 
NFKB1 2.2 1.1 
 
0.7 0.6 
 
NS 
NFKB2 2.3 0.3 
 
2.4 0.5 
 
NS 
NFKBIA 2.3 1.1 
 
1.0 0.8 
 
NS 
NFKBIB 2.4 1.5 
 
1.9 1.3 
 
NS 
NFKBIE 2.7 1.1 
 
1.4 1.1 
 
NS 
PEA15 2.5 0.7 
 
2.3 0.9 
 
NS 
PMAIP1 2.7 1.1 
 
0.8 0.9 
 
NS 
REL 2.8 1.0 
 
2.0 0.7 
 
NS 
RELA 1.6 0.5 
 
1.6 0.8 
 
NS 
RELB 9.0 3.6 
 
7.5 2.9 
 
NS 
RIPK1 2.2 1.7 
 
1.7 1.4 
 
NS 
TA-NFKBH 2.1 1.0 
 
2.2 1.4 
 
NS 
TBK1 2.6 1.6 
 
0.8 0.7 
 
NS 
TNF 8.0 2.4 
 
3.1 1.6 
 
0.02 
TNFRSF10A 8.8 2.0 
 
2.7 1.2 
 
0.01 
TNFRSF10B 2.2 0.6 
 
1.5 0.7 
 
NS 
TNFRSF1A 1.2 0.7 
 
1.2 0.6 
 
NS 
TNFRSF1B 14.3 3.3 
 
2.0 1.1 
 
0.01 
TNFRSF21 1.8 1.0 
 
3.3 1.5 
 
NS 
TNFRSF25 8.8 2.5 
 
0.9 0.8 
 
0.00 
TNFSF10 10.3 1.6 
 
0.8 0.9 
 
0.00 
TRADD 2.8 1.3 
 
0.7 0.7 
 
NS 
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Supplemental Table 2-2. Schematic depicts known effects of DHFR 
inhibition and new pathway described herein.  
 
Supplemental Table 3-1. Demographic characteristics of the RA 
patients and healthy controls and clinical characteristics of the RA 
patients* 
   
Controls 
RA,  
no MTX 
treament 
RA, MTX 
treatment 
 
   
(n=43) (n=18) (n=24)  
Age, mean ± SD yrs 
 
44 ± 11 46 ± 11 48 ± 15  
Female 
 
74 78 100  
Ethnicity 
  
   
Caucasian 
 
74 94 80  
African American 
 
15 6 15  
Hispanic 
 
6 0 5  
Asian 
 
6 0 0  
Clinical characteristics 
 
  
      Disease Duration, mean ± SD years - 10 ± 9 9 ± 7 
      Active Disease ‡ 
 
- 72 68 
 Early RA (disease duration < 1 year) - 22 17 
 Treatment 
           HCQ 
  
- 44 39 
      Steroids 
  
- 39 61 
      TNF Inhibitors 
 
- 44 28 
  
* Except where indicated otherwise, values are the percent.  
‡ Defined as the presence of at least 3 of the following: morning stiffness > 45 
minutes, > 3 swollen joints, > 6 tender joints, and erythrocyte sedimentation > 28 
mm/hour. Abbreviations: RA, rheumatoid arthritis; MTX, methotrexate; HCQ, 
hydroxychloroquine; TNF = tumor necrosis factor  
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Supplemental Table 3-2. Gene expression studies reveal statistically 
significant differences in MAPK9 expression in patients diagnosed 
with rheumatoid arthritis (RA). Mitogen-activated protein kinases 
(MAPKs) were assayed in control (CTRL, N=43) and RA subjects 
(N=18). Expression values are relative to GAPDH. P values are 
calculated relative to controls.  
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Supplemental Table 5-1. Characteristics of the control and 
autoimmune subject populations 
	  
   
Controls RA SLE SS 
   
(n=45) (n=36) (n=24) (n=12) 
Age, mean ± SD yrs 
 
38 ± 11 51 ± 14 42 ± 13 47 ± 13  
Female 
 
73 94 94 82 
Ethnicity 
  
   
Caucasian 
 
58 83 45 58 
African American 
 
22 11 33 25 
Hispanic 
 
13 6 11 17 
Asian 
 
7 - 11 - 
Disease Duration, mean ± SD years - - § 8 ± 2 
       Characteristics of RA Subjects  
 
(-MTX) (+MTX) 
 
    
(n = 18) (n = 18) 
 Disease Duration, mean ± SD years 
 
10 ± 9 9 ± 7 
 Active Disease ‡ 
 
- 72 68 
 Early RA (disease duration < 1 year) - 22 17 
 Treatment 
           HCQ 
  
- 44 39 
      Steroids 
  
- 39 61 
      TNF Inhibitors 
 
- 44 28 
 	  
	  
	  
* Except where indicated otherwise, values are the percent.  
‡ Defined as the presence of at least 3 of the following: morning stiffness > 45 
minutes, > 3 swollen joints, > 6 tender joints, and erythrocyte sedimentation > 28 
mm/hour. § Data are unavailable. Abbreviations: RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; SS, Sjögren’s syndrome; MTX, methotrexate; HCQ, 
hydroxychloroquine  
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Supplemental Figure 5-1. Schematic representation of the 
chromosomal location of the lincRNA-p21 gene locus. Arrowheads 
indicate the orientation of transcription. 
 
Reprinted with permission from: Huarte et al. “A Large Intergenic Noncoding 
RNA Induced by p53 Mediates Global Gene Repression in the p53 Response.” 
Cell. 2010. p409-419. License No. 3352140680943 
